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                                                    INTRODUCTION 
1.1 LIVER:
                    Liver is the largest internal organ in the body, constituting about 2.5% of
an adult’s body weight.  During rest,  it  receives 25% of the cardiac output via the
hepatic portal vein and hepatic artery. The hepatic portal vein carries the absorbed
nutrients from the GI tract to the liver, which takes up, stores, and distributes nutrients
and vitamins. The liver plays an important role in maintaining blood glucose levels. It
also  regulates  the  circulating  blood  lipids  by  the  amount  of  very  low  density
lipoproteins  (VLDLs)  it  secretes.  Many  of  the  circulating  plasma  proteins  are
synthesized by the liver. In addition, the liver takes up numerous toxic compounds
and drugs from the portal circulation. It is well equipped to deal with the metabolism
of drugs and toxic substances. The liver also serves as an excretory organ for bile
pigments, cholesterol, and drugs. Finally, it performs important endocrine functions.1
1.1.1 Anatomy of the Liver
The liver  is  almost  completely covered by visceral  peritoneum and is  completely
covered by a dense irregular connective tissue layer that lies deep to the peritoneum.
The liver is divided into two principal lobes a large right lobe and a smaller left lobe
by the falciform ligament, a fold of the mesentery (Figure 24.14a). Although the right
lobe is  considered by many anatomists to include an inferior  quadrate lobe  and a
posterior  caudate lobe,  based on internal morphology (primarily the distribution of
blood vessels), the quadrate and caudate lobes more appropriately belong to the left
lobe. The falciform ligament extends from the undersurface of the diaphragm between
the two principal lobes of the liver to the superior surface of the liver, helping to
suspend the liver in the abdominal cavity. In the free border of the falciform ligament
is the ligamentum teres (round ligament), a remnant of the umbilical vein of the fetus
this fibrous cord extends from the liver to the umbilicus. The right and left coronary
ligaments are narrow extensions of the parietal peritoneum that suspend the liver from
the diaphragm.
1.1.2 The Liver Can Regenerate
Of the solid organs, the liver is the only one that can regenerate. There appears to be a
critical ratio between functioning liver mass and body mass. Deviations in this ratio
trigger  a  modulation  of  either  hepatocyte  proliferation  or  apoptosis,  in  order  to
maintain the liver’s optimal size. Peptide growth factors such as transforming growth
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factor- α  (TGF- α),  hepatocyte growth factor (HGF), and epidermal growth factor
(EGF) have been the best-studied stimuli of hepatocyte DNA synthesis. After these
peptides bind to  their receptors  on the remaining hepatocytes  and work their way
through myriad transcription factors,  gene transcription is  accelerated,  resulting in
increased  cell  number  and increased  liver  mass.  Alternatively,  a  decrease  in  liver
volume is achieved by enhanced hepatocyte apoptosis rates. Apoptosis is a carefully
programmed process by which cells kill themselves while maintaining the integrity of
their cellular membranes. In contrast, cell death that results from necroinflammatory
processes is characterized by a loss of cell membrane integrity and the activation of
inflammatory reactions. Liver cell suicide is mediated by proapoptotic signals, such as
tumor necrosis factor (TNF).
1.1.3 Histology of the liver.
Histologically,  the  liver  is  composed  of  hepatocytes,  bile  canaliculi,  and  hepatic
sinusoids as shown in fig 1& 2.
1. Hepatocytes (hepat- liver; cytes cell). 
            Hepatocytes are the major functional cells of the liver and perform a wide
array of metabolic, secretory, and endocrine functions. These are specialized epithelial
cells  with  5  to  12  sides  that  make  up  about  80%  of  the  volume  of  the  liver.
Hepatocytes form complex three-dimensional arrangements called hepatic laminae.
Fig 1: Histological view of the Liver
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Fig 2: photomicrographs of the liver
The  hepatic  laminae  are  plates  of  hepatocytes  one  cell  thick  bordered  on  either
side by the endothelial-lined vascular  spaces called hepatic sinusoids.  The hepatic
laminae  are  highly branched,  irregular  structures.  Grooves  in  the  cell  membranes
between neighboring hepatocytes provide spaces for canaliculi (described next) into
which the hepatocytes secrete bile.  Bile,  a yellow,  brownish,  or olive-green liquid
secreted by hepatocytes, serves as both an excretory product and a digestive secretion.
                                             Hepatic stellate cells 
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Fig 3: The chief cellular features of a hepatic cord, showing hepatocytes, grooved by bile
canaliculi. A discontinuous fenestrated endothelium lines the sinusoids, shown containing
erythrocytes. Also shown are a Kupffer cell and a hepatic stellate cell. Fine collagen fibres
occupy the space of Disse.
Hepatic stellate cells are also known as perisinusoidal lipocytes or Ito cells and are
much less numerous than hepatocytes. They are irregular in outline and lie within the
hepatic plates, between the bases of hepatocytes. They are thought to be mesenchymal
in origin and are characterized by numerous cytoplasmic lipid droplets. These cells
secrete  most  of  the  intralobular  matrix  components,  including  collagen  type  III
(reticular) fibres. They store the fat-soluble vitamin A in their lipid droplets and are a
significant  source  of  growth  factors  active  in  liver  homeostasis  and  regeneration.
Hepatic stellate cells also play a major role in pathological processes. In response to
liver damage, they become activated and predominantly myofibroblast-like. They are
responsible for the replacement of toxically damaged hepatocytes with collagenous
scar tissue - hepatic fibrosis, seen initially in zone 3, around central veins. This can
progress to cirrhosis, where the parenchymal architecture and pattern of blood flow
are destroyed, with major systemic consequences. 
2. Sinusoidal endothelial cells 
              Hepatic venous sinusoids are generally wider than blood capillaries and are
lined by a thin but highly fenestrated endothelium which lacks a basal lamina. The
endothelial cells are typically flattened, each with a central nucleus and joined to each
other by junctional  complexes. The fenestrae are grouped in clusters with a mean
diameter of 100nm, allowing plasma direct access to the basal plasma membranes of
hepatocytes. Their cytoplasm contains numerous typical transcytotic vesicles. 
3. Kupffer cells 
              Kupffer cells are hepatic macrophages derived from circulating blood
monocytes. They are long-term hepatic residents, lying within the sinusoidal lumen,
attached to the endothelial surface. They originate in the bone marrow, and form a
major part of the mononuclear phagocyte system, responsible for removing cellular
and  microbial  debris  from  the  circulation,  and  secreting  cytokines  involved  in
defence.  Kupffer  cells  remove  aged  and  damaged  red  cells  from  the  hepatic
circulation, a function normally shared with the spleen, but fulfilled entirely by the
liver  after  splenectomy.  Kupffer  cells  are  irregular  in  shape,  with  long  processes
extending into the sinusoidal lumen. 
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Fig 4: Details of hepatic acinus
4. Bile canaliculi (kan-a-LIK-u- -li small canals). 
These are small ducts between hepatocytes that collect bile produced by
the hepatocytes. From bile canaliculi, bile passes into bile ductules and then bile
ducts. The bile ducts merge and eventually form the larger right and left hepatic
ducts, which unite and exit the liver as the common hepatic duct. The common
hepatic duct joins the cystic duct (cystic bladder) from the gallbladder to form the
common bile  duct.  From here,  bile  enters  the  small  intestine  to  participate  in
digestion.
Fig 5: Comparision of three units of liver structure and function
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5. Hepatic sinusoids. 
These are highly permeable blood capillaries between rows of hepatocytes
that  receive  oxygenated  blood  from  branches  of  the  hepatic  artery  and
nutrient-rich deoxygenated blood from branches  of  the hepatic  portal  vein.
Recall  that  the  hepatic  portal  vein  brings  venous  blood  from  the
gastrointestinal organs and spleen into the liver. Hepatic sinusoids converge
and deliver blood into a central vein. From central veins the blood flows into
the hepatic veins, which drain into the inferior vena cava. In contrast to blood
which flows toward a central vein, bile flows in the opposite direction. Also
present in the hepatic sinusoids are fixed phagocytes called stellate reticulo
endothelial (Kupffer) cells, which destroy worn-out white and red blood cells,
bacteria,  and  other  foreign  matter  in  the  venous  blood  draining  from  the
gastrointestinal tract. Together, a bile duct, branch of the hepatic artery, and
branch of  the hepatic  vein are referred to as  a  portal  triad (tri  three).  The
hepatocytes,  bile  duct  system,  and hepatic  sinusoids  can  be organized into
anatomical and functional units in three different ways:
1. Hepatic  lobule.  For  years,  anatomists  described  the  hepatic  lobule  as  the
functional unit of the liver. According to this model, each hepatic lobule is shaped like
a hexagon (six-sided structure) left at its center is the central vein, and radiating out
from it are rows of hepatocytes and hepatic sinusoids. Located at three corners of the
hexagon is a portal triad. This model is based on a description of the liver of adult
pigs.  In  the  human  liver  it  is  difficult  to  find  such  well-defined  hepatic  lobules
surrounded by thick layers of connective tissue.
2. Portal lobule. This model emphasized the exocrine function of the liver, that
is, bile secretion. Accordingly, the bile duct of a portal triad is taken as the center of
the portal  lobule.  The portal  lobule is  triangular  in shape and is  defined by three
imaginary straight lines that connect three central veins that are closest to the portal
triad. This model has not gained widespread acceptance.
3. Hepatic acinus. In recent years, the preferred structural and functional unit of
the liver is the hepatic acinus. Each hepatic acinus is an approximately oval mass that
includes portions of two neighboring hepatic lobules. The short axis of the hepatic
acinus is defined by branches of the portal triad branches of the hepatic artery, vein,
and bile ducts that run along the border of the hepatic lobules. The long axis of the
acinus is defined by two imaginary curved lines, which connect the two central veins
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closest to the short axis (Figure 24.15e, center). Hepatocytes in the hepatic acinus are
arranged in three zones around the short axis, with no sharp boundaries between them.
Cells in zone 1 are closest to the branches of the portal triad and the first to receive
incoming oxygen, nutrients, and toxins from incoming blood. These cells are the first
ones to take up glucose and store it as glycogen after a meal and break down glycogen
to glucose  during fasting.  They are  also the  first  to  show morphological  changes
following bile duct obstruction or exposure to toxic substances. Zone 1 cells are the
last ones to die if circulation is impaired and the first ones to regenerate Cells in zone
3 are farthest from branches of the portal triad and are the last to show the effects of
bile obstruction or exposure to toxins, the first ones to show the effects of impaired
circulation, and the last ones to regenerate. Zone 3 cells also are the first to show
evidence  of  fat  accumulation.  Cells  in  zone  2  have  structural  and  functional
characteristics intermediate between the cells in zones 1 and 3. The hepatic acinus is
the smallest structural and functional unit of the liver. Its popularity and appeal are
based on the fact that it provides a logical description and interpretation of (1) patterns
of glycogen storage and release and (2) toxic effects, degeneration, and regeneration
in  the  three  zones  of  the  hepaticacinus  relative  to  the  proximity of  the  zones  to
branches of the portal triad.
1.1.4 Role and Composition of Bile
Role and Composition of Bile Each day, hepatocytes secrete 800–1000 mL (about 1
qt)  of  bile,  a  yellow,  brownish,  or  olive-green liquid.  It  has a  pH of  7.6–8.6 and
consists  mostly of water,  bile salts, cholesterol,  a phospholipid called lecithin, bile
pigments, and several ions. The principal bile pigment is bilirubin. The phagocytosis
of aged red blood cells liberates iron, globin, and bilirubin (derived from heme). The
iron and globin are recycled; the bilirubin is secreted into the bile and is eventually
broken down in the intestine. One of its breakdown products stercobilin gives feces
their  normal  brown  color.  Bile  is  partially  an  excretory  product  and  partially  a
digestive secretion. Bile salts, which are sodium salts and potassium salts of bile acids
(mostly chenodeoxycholic acid and cholic  acid),  play a role in emulsification, the
breakdown of large lipid globules into a suspension of small lipid globules. The small
lipid globules present a very large surface area that allows pancreatic lipase to more
rapidly accomplish digestion of triglycerides. Bile salts also aid in the absorption of
lipids following their digestion. Although hepatocytes continually release bile, they
increase production and secretion when the portal  blood contains more bile acids;
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thus, as digestion and absorption continue in the small intestine, bile release increases.
Between meals, after most absorption has occurred, bile flows into the gallbladder for
storage because the sphincter of the hepatopancreatic ampulla (sphincter of Oddi; see
Figure 24.14) closes off the entrance to the duodenum.
1.1.5 Functions of the Liver
In addition to secreting bile, which is needed for absorption of dietary fats, the liver
performs many other vital functions:
• Carbohydrate metabolism. The liver is especially important in maintaining a normal
blood glucose level. When blood glucose is low, the liver can break down glycogen to
glucose  and  release  the  glucose  into  the  bloodstream.  The  liver  can  also  convert
certain amino acids and lactic acid to glucose and it can convert other sugars, such as
fructose and galactose, into glucose. When blood glucose is high, as occurs just after
eating a meal, the liver converts glucose to glycogen and triglycerides for storage.
•  Lipid metabolism. Hepatocytes store some triglycerides; break down fatty acids to
generate ATP; synthesize lipoproteins, which transport fatty acids, triglycerides, and
cholesterol to and from body cells; synthesize cholesterol; and use cholesterol to make
bile salts.
• Protein metabolism. Hepatocytes deaminate (remove the amino group, NH2, from)
amino acids so that the amino acids can be used for ATP production or converted to
carbohydrates or fats. The resulting toxic ammonia (NH3) is then converted into the
much less toxic urea, which is excreted in urine. Hepatocytes also synthesize most
plasma  proteins,  such  as  alpha  and  beta  globulins,  albumin,  prothrombin,  and
fibrinogen.
•  Processing of  drugs  and hormones.  The liver  can  detoxify substances  such  as
alcohol  and excrete drugs such as  penicillin,  erythromycin,  and sulfonamides  into
bile. It  can also chemically alter or excrete thyroid hormones and steroid hormones
such as estrogens and aldosterone.
•  Excretion of bilirubin.  As previously noted, bilirubin, derived from the heme of
aged red blood cells, is absorbed by the liver from the blood and secreted into bile.
Most  of the bilirubin in bile  is  metabolized in the small  intestine by bacteria and
eliminated in feces.
• Synthesis of bile salts. Bile salts are used in the small intestine for the emulsification
and absorption of lipids.
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• Storage. In addition to glycogen, the liver is a prime storage site for certain vitamins
(A, B12, D, E, and K) and minerals (iron and copper), which are released from the
liver when needed elsewhere in the body.
•  Phagocytosis.  The  stellate  reticuloendothelial  (Kupffer)  cells  of  the  liver
phagocytize aged red blood cells, white blood cells, and some bacteria.
• Activation of vitamin D. The skin, liver, and kidneys participate in synthesizing the
active form of vitamin D.2
1.1.6 ENDOCRINE FUNCTIONS OF THE LIVER
The  liver  is  important  in  regulating  the  endocrine  functions  of  hormones.  It  can
amplify the action of some hormones. It is also the major organ for the removal of
peptide hormones.
1.1.7 The Liver Can Modify or Amplify Hormone Action
As discussed before,  the liver converts  vitamin D3 to 25-hydroxy vitamin D3,  an
essential step before conversion to the active hormone 1,25-hydroxy vitamin D3 in
the kidneys.  The liver  is  also  a  major  site  of  conversion of  the thyroid hormone
thyroxine (T4) to the biologically more potent hormone triiodothyronine (T3). The
regulation of the hepatic T4 to T3 conversion occurs at both the uptake step and the
conversion step. Due to the liver’s relatively large reserve in converting T4 to T3,
hypothyroidism is uncommon in patients with liver disease. In advanced chronic liver
disease,  however,  signs of hypothyroidism may be evident. The liver modifies the
function  of  growth  hormone  (GH)  secreted  by  the  pituitary  gland.  Some growth
hormone actions are mediated by insulin-like growth factors made by the liver.
1.1.8 The Liver Removes Circulating Hormones
The  liver  helps  to  remove  and  degrade  many  circulating  hormones.  Insulin  is
degraded in many organs, but the liver and kidneys are by far most important. The
presence of insulin receptors on the surface of hepatocytes suggests that the binding
of insulin to these receptors results in degradation of some insulin molecules. There is
also degradation of insulin by proteases of hepatocytes that do not involve the insulin
receptor. Glucagon and growth hormone are degraded mainly by the liver and the
kidneys.  The liver  may also  degrade  various  GI hormones  (e.g.,  gastrin),  but  the
kidneys and other organs probably contribute more significantly to inactivating these
hormones.
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1.1.9 The Liver Is Important in the Storage and Homeostasis of Iron
The  liver  is  the  major  site  for  the  synthesis  of  several  proteins  involved  in  iron
transport and metabolism. The protein transferrin plays a critical role in the transport
and  homeostasis  of  iron  in  the  blood.  The  circulating  plasma  transferrin  level  is
inversely proportional to the iron load of the body the higher the concentration of
ferritin  in  the  hepatocyte,  the  lower  the  rate  of  transferrin  synthesis.  During  iron
deficiency,  liver  synthesis  of  transferrin  is  significantly  stimulated,  enhancing  the
intestinal  absorption  of  iron.  Haptoglobin,  a  large  glycoprotein  with  a  molecular
weight of 100,000, binds free hemoglobin in the blood. The hemoglobin-haptoglobin
complex is rapidly removed by the liver, conserving iron in the body. Hemopexin is
another protein synthesized by the liver that is involved in the transport of free heme
in the blood. It forms a complex with free heme, and the complex is removed rapidly
by the liver.  The spleen is the organ that removes red blood cells that are slightly
altered. Kupffer cells of the liver also have the capacity to remove damaged red blood
cells, especially those that are moderately damaged (Fig. 28.8). 
The red cells taken up by Kupffer cells are rapidly digested by secondary lysosomes
to release heme. Microsomal  heme oxygenase releases iron from the heme, which
then enters the free iron pool and is stored as ferritin or released into the bloodstream
(bound to apotransferrin). Some of the ferritin iron may be converted to hemosiderin
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The possible pathways following phagocytosis of damaged red blood cells by Kupffer 
cells.
granules.  It  is  unclear  whether  the  iron  from  the  hemosiderin  granules  is
exchangeable with the free iron pool.
It was long believed that Kupffer cells were the only cells involved in iron storage,
but  recent  studies  suggest  that  hepatocytes  are  the  major  sites  of  long-term iron
storage. Transferrin binds to receptors on the surface of hepatocytes, and the entire
transferrin-receptor complex is internalized and processed (Fig. 28.9).
The  apotransferrin  (not  containing  iron)  is  recycled  back  to  the  plasma,  and  the
released iron enters a labile iron pool. The iron from transferrin is probably the major
source  of  iron  for  the  hepatocytes,  but  they  also  derive  iron  from  haptoglobin-
hemoglobin and hemopexin-heme complexes.  When hemoglobin is  released inside
the hepatocytes,  it  is  degraded in the secondary lysosomes, and heme is released.
Heme is processed in the smooth ER and free iron released enters the labile iron pool.
A significant portion of the free iron in the cytosol probably combines rapidly with
apoferritin to form ferritin. Like Kupffer cells, hepatocytes may transfer some of the
iron  in  ferritin  to  hemosiderin.  Iron  is  absolutely  essential  for  survival,  but  iron
overload  can  be  extremely  toxic,  especially  to  the  liver  where  it  can  cause
hemochromatosis, a condition characterized by excessive amounts of hemosiderin in
the hepatocytes. The hepatocytes in patients with hemochromatosis are defective and
fail to perform many normal functions.3
1.2 DRUG-INDUCED LIVER INJURY (DILI)
The  number  of  drugs  associated  with  adverse  reactions  involving  the  liver  is
extensive. One of the more common reasons for the withdrawal of a drug from the
marketplace is  an elevation of liver enzymes.4 Alcohol-induced liver disease is the
most common type of drug-induced liver disease. All other drugs together account for
less than 10% of patients hospitalized for elevated liver enzymes.5 In approximately
75% of these cases liver transplantation is ultimately required for patient survival. The
liver’s function affects almost every other organ system in the body.
1.2.1 PATTERNS OF DRUG-INDUCED LIVER DISEASE
For some drugs, a genetic or acquired abnormality must exist in a particular metabolic
pathway for a toxic reaction to take place (Fig. 38–1). In other cases, the reactions are
typically associated with a drug concentration and often respond to simply lowering
the dose  of  the  drug.  Idiosyncratic  reactions  tend to  occur  without  association to
particular blood concentrations or specifically identified metabolic abnormalities. For
example, sulfonylureas like glipizide and antibiotics like ciprofloxacin have caused
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severe liver disease, resulting in the need for transplantation in a very small group of
patients.6,7 
1.2.3 ALLERGIC HEPATITIS
Allergic  reactions  in  the  liver  can  be  caused  by many drugs  and  result  in  many
different kinds of hepatic damage. Trimethoprim sulfamethoxazole and penicillinase-
resistant  penicillins  such  as  dicloxacillin  induce  a  reaction  typical  of  hepatic
hypersensitivity in a few patients. The reaction usually develops within 4 weeks of the
start  of  therapy.8,9 It  is  marked by fever,  pruritus,  rash,  eosinophilia,  arthritis,  and
hemolytic  anemia.  The formation of  granulomas within the liver  is  often seen on
biopsy.10 The  reaction  reverses  with  discontinued  therapy  and  reappears  upon
rechallenge.  Most  antibiotics  have  been  associated  with  this  type  of  reaction,
including the fluoroquinolones, macrolides, and β-lactams.3 Allopurinol also has been
associated with a number of reports of hypersensitivity reactions involving the liver.
The onset of symptoms is 1 to 6 weeks after initiation of therapy. The incidence, like
all  the  allergic  liver  reactions,  is  low,  estimated  at  less  than  1%.  The  clinical
presentation includes eosinophilia, fever, rash, and arthritis, as previously mentioned.
The biopsy may showa pattern of fibrin-ring granulomas similar to those seen in Q
fever.11
1.2.4 TOXIC HEPATITIS
Toxic reactions are predictable, often dose-related effects in the liver due to specific
agents.  When  taken  in  overdose,  acetaminophen  becomes  bioactivated  to  a  toxic
intermediate  known  as  N-acetyl-p-benzoquinone  imine  (NAPQI).  NAPQI  is  very
reactive, with a high affinity for sulfhydryl groups. When the liver’s glutathione stores
are  depleted  and  there  are  no  longer  sulfhydryl  groups  available  to  detoxify this
metabolite,  it  begins  to  react  directly  with  the  hepatocyte  (see  Fig.  38–1).
Replenishing  the  liver’s  sulfhydryl  capacity  through  the  administration  of  N-
acetylcysteine  early  after  ingestion  of  the  overdose  halts  this  process.12
Acetaminophen’s toxicity occurs in four stages.13 Reye’s syndrome is an aggressive
form of toxic hepatitis often associated with aspirin use in children. Valproate toxicity
can  also  present  in  this  pattern.  Early  in  the  process  of  Reye’s  syndrome,
mitochondrial dysfunction leads to the depletion of acyl coenzyme A and carnitine.
Fatty acids accumulate and gluconeogenesis is impaired, resulting in hypoglycemia. A
concurrent disruption of the urea cycle occurs, leading to a decrease in the removal of
ammonia and a slowing of protein use. A threefold rise in the blood ammonia level
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and an increase in the prothrombin time are common findings. In advanced stages of
Reye’s syndrome, many patients develop intracranial  hypertension that  can be life
threatening and refractory to therapy.14,15
1.2.5 Biotransformation of a drug is explained as follows:
1. The drug is  actively transported  into the  hepatocyte  by the organic  anion
transport pump, a transmembrane protein. 
2. The metabolite (drug) interacts with one of a number of enzymes, the most
common being CYP3A4. The CYPx family of phase I enzymes are regulated
by the complementary DNA xenobiotic receptor. The xenobiotic receptor is in
turn upregulated by other drugs, changes in cholesterol catabolism, and bile
acids. 
3. The immediate result of the action of the phase I enzyme is the production of
an unstable metabolite. 
4. The unstable metabolite then reacts with glucuronidase, various transferases,
or  hydroxylases  to  form  a  conjugated  metabolite.  The  efficacy  of  these
enzymes  is  affected  by  the  patient’s  nutritional  state  and  genetic
polymorphism, leading to variations in individual risk for toxicity. 
5. The conjugated metabolite is removed from the hepatocyte by the canalicular
membrane export pump, one of a large family of membrane proteins (other
members of this family pump conjugated metabolites back into the blood for
excretion by the kidney). These proteins are subject to genetic polymorphism
as well, again leading to some patients having an increased risk for toxicity. 
6. If  unable  to  form  a  conjugate,  the  unstable  metabolite  can  participate  in
oxidative reactions that damage lipids, proteins, or even DNA. 
7. Alternatively the  unstable  metabolite  may form damaging  covalent  bonds
with available anions or cations.
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1.2.6 CHRONIC ACTIVE TOXIC HEPATITIS
Dantrolene, isoniazid, phenytoin, nitrofurantoin, and trazodone have been reported in
association  with  a  type  of  autoimmune  mediated  disease  in  the  liver.16,17 Patients
experience periods of symptomatic hepatitis followed by periods of convalescence,
only to repeat the experience months later. It  is a progressive disease with a high
mortality rate  and is  more common in females than males.  Antinuclear  antibodies
appear in most patients. These drugs appear to form antiorganelle antibodies.18 The
exact identification of a causative agent is sometimes difficult since diagnosis requires
mu ltiple episodes occurring long after exposure to the offending drug.
1.2.7 TOXIC CIRRHOSIS
The scarring effect  of  hepatitis  in  the liver  leads  to  the development  of  cirrhosis.
Some drugs tend to cause such a mild case of hepatitis that it may not be detected.
Mild hepatitis can be easily mistaken for a more routine generalized viral infection. If
the offending drug or agent is not discontinued, this damage will continue to progress.
The patient eventually presents not with hepatitis, but with cirrhosis. Methotrexate
causes periportal fibrosis in most patients who experience hepatotoxicity. The lesion
results from the action of a bioactivated metabolite produced by cytochrome P450.19
This  process  has  most  commonly been  noted  in  patients  treated for  psoriasis  and
arthritis. The extent of damage can be reduced or controlled by increasing the dosage
interval to once weekly or by routine use of folic acid supplements.20
Vitamin A is normally stored in liver cells, and causes significant hypertrophy and
fibrosis  when  taken  for  long  periods  in  high  doses.  Hepatomegaly is  a  common
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A general diagram of biotransformation of a drug
finding,  along  with  ascites  and  portal  hypertension.  In  patients  with  vitamin  A
toxicity, gingivitis and dry skin are also very common. This is accelerated by ethanol,
which competes with retinol for aldehyde dehydrogenase.21
1.3 LIVER VASCULAR DISORDERS
Focal lesions in hepatic venules, sinusoids, and portal veins occur with various drugs.
The most commonly associated drugs are the cytotoxic agents used to treat cancer, the
pyrrolizidine alkaloids, and the sex hormones. A centralized necrosis often follows
and can result in cirrhosis. Azathioprine and herbal teas that contain comfrey (a source
of  pyrrolizidine  alkaloids)  are  associated  with  the  development  of  veno-occlusive
disease. The exact incidence is rare and may be dose related.3 Peliosis hepatitis is a
rare type of hepatic vascular lesion that can be seen as both an acute and a chronic
disease.  The  liver  develops  large,  blood-filled  lacunae  within  the  parenchyma.
Rupture of the lacunae can lead to severe peritoneal hemorrhage. Peliosis hepatitis has
been  associated  with  exposure  of  the  liver  to  androgens,  estrogens,  tamoxifen,
azathioprine,  and  danazol.  Androgens  with  a  methyl  alkylation  at  the  17  carbon
position  of  the  testosterone  structure  are  the  most  frequently reported  agents  that
cause peliosis hepatitis, usually after at least 6 months of therapy.22
1.4 MECHANISMS OF DRUG-INDUCED LIVER DISEASE
1.4.1 CENTROLOBULAR NECROSIS
Centrolobular necrosis is often a dose-related, predictable reaction secondary to drugs
such  as  acetaminophen;  however,  it  also  can  be  associated  with  idiosyncratic
reactions, such as those caused by halothane. Also called direct or metabolite-related
hepatotoxicity, centrolobular necrosis is usually the result of the production of a toxic
metabolite (see Fig. 38–1). The damage spreads outward from the middle of a lobe of
the liver. Patients suffering from centrolobular necrosis tend to present in one of two
ways, depending on the extent of necrosis. Mild drug reactions, involving only small
amounts of parenchymal tissue, may be detected as asymptomatic elevations in the
serum transaminases. If the reaction is diagnosed at this stage, most of these patients
will recover with minimal cirrhosis and thus minimal chronic liver impairment. More
severe forms of centrolobular necrosis are accompanied by nausea, vomiting, upper
abdominal pain, and jaundice.23
1.4.2  STEATOHEPATITISSteatohepatitis  (also  known  as  steatonecrosis)  is  a
specialized type of acute necrosis resulting from the accumulation of fatty acids in the
hepatocyte.  Drugs or their metabolites that cause steatonecrosis do so by affecting
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fatty-acid  oxidation  within  the  mitochondria  of  the  hepatocyte  (see  Fig.  38–1).
Hepatic  vesicles  become  engorged  with  fatty  acids,  eventually  disrupting  the
homeostasis of the hepatocyte. The liver biopsy is marked by a massive infiltration by
polymorphonuclear leukocytes, degeneration of the hepatocytes, and the presence of
Mallory bodies.3  Alcohol is  the drug that  most commonly produces steatonecrotic
changes in the liver. When alcohol is converted into acetaldehyde, the synthesis of
fatty acids is increased.24,25   When the hepatocyte has become completely engorged
with  microvesicular  fat,  it  often  breaks  open,  spilling  into  the  blood.  If  enough
hepatocytes break open, an inflammatory response begins. If the offending agent is
withdrawn before significant numbers of hepatocytes become necrotic, the process is
completely reversible without long-term sequelae. In nonalcoholic steatohepatitis the
same endpoint is often achieved through oxidation of lipid peroxidases.26 Tetracycline
produces steatohepatitis and steatosis.27 The lesions are characterized by large vesicles
of fat found diffused throughout the liver.. The mortality of tetracycline steatohepatitis
is very high (70% to 80%), and those who do survive often develop cirrhosis. Sodium
valproate  also  can  produce  steatonecrosis  through  the  process  of  bioactivation.
Cytochrome  P450  converts  valproate  to  D-4-valproic  acid,  a  potent  inducer  of
microvesicular fat accumulation.28
1.4.3 PHOSPHOLIPIDOSIS
Phospholipids usually engorge the lysosomal bodies of the hepatocyte.26  Amiodarone
has been associated with this reaction. Patients treated with amiodarone who develop
overt hepatic disease tend to have received higher doses of the drug. These patients 
also have higher amiodarone to N-desethyl-amiodarone ratios,  indicating a greater
accumulation  of  the  parent  compound.  Amiodarone  and  its  major  metabolite  N-
desethyl-amiodarone  remain  in  the  liver  of  all  patients  for  several  months  after
therapy is stopped. Usually the phospholipidosis develops in patients treated for more
than  1  year.  The  patient  can  present  with  either  elevated  transaminases  or
hepatomegaly; jaundice is rare.
1.4.4 GENERALIZED HEPATOCELLULAR NECROSIS
Generalized  hepatocellular  necrosis  mimics  the  changes  associated  with  the  more
common viral hepatitis. The onset of symptoms is usually delayed as much as a week
or more after exposure to toxin. Bioactivation is often important for toxic hepatitis to
develop,  but  may  not  be  the  immediate  cause  of  damage.  Many  drugs  that  are
associated with toxic hepatitis produce metabolites that are not inherently toxic to the
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liver. Instead, they act as haptens, binding to specific cell proteins and inducing an
autoimmune reaction (see Fig.  38–1).  The rate  of  bioactivation can  vary between
males and females and between individuals of the same sex.,29 The cytochrome P450
system (CYP) tends to metabolize lipophilic substrates which are actively pumped
into the hepatocyte by an organic anion (or cation) transporting protein. The CYP
subspecies  1A,  2B,  3A,  and  4A are  regulated  by the  highly inducible  xenobiotic
receptor on complementary DNA. The receptor is found in the liver, and to a lesser
extent  in  the  cells  lining  the  intestinal  tract,  and  is  responsible  for  cholesterol
catabolism and bile acid homeostasis. The activity of this receptor is subject to genetic
polymorphism  as  well.  This  results  in  a  wide  variation  in  the  sensitivity  of  the
population  to  generalized  hepatocellular  necrosis  and  other  forms  of  hepatic
damage.23,30 The long-term administration of isoniazid can lead to hepatic dysfunction
in 10% to 20% of those receiving the drug. Yet severe toxic hepatitis develops in only
1% or less of this population.31 The N-acetyltransferase 2 (NAT2) genotype appears to
play a role in determining a patient’s relative risk.  In  one study,  patients with the
slowtype  NAT2  genotype  had  a  28-fold  greater  risk  of  developing  serum
aminotransferase  elevations  than  did  patients  with  the  fast-type  NAT genotype.32
Isoniazid is metabolized by several pathways, acetylation being the major pathway. It
is acetylated to acetylisoniazid, which, in turn, is hydrolyzed to acetylhydrazine.33 The
acetylhydrazine,  and to a lesser extent the acetylisoniazid, are directly toxic to the
cellular proteins in the hepatocyte, but rapid acetylators also detoxify acetylhydrazine
very rapidly, converting it to diacetylhydrazine (a nontoxic metabolite). Ketoconazole
produces generalized hepatocellular necrosis or milder forms of hepatic dysfunction
in 1% to 2% of patient’s treated for fungal infections. This reaction is fatal in high
numbers of patients infected with the human immunodeficiency virus. The onset is
usually early in therapy, although it can be delayed until several months into therapy.
In immune-compromised patients in whom ketoconazole is used for long periods of
time, special care should be taken to watch for changes in liver function.34
1.4.5 CHOLESTATIC JAUNDICE
Cholestatic  jaundice,  or  cholestasis,  can  be  classified  by  the  area  of  the  bile
canalicular  or  ductal  system that  is  impaired.  Canalicular cholestasis  is  very often
associated with long-term high-dose estrogen therapy. Clinically,  these patients are
often asymptomatic and present with mild to moderate elevations of serum bilirubin.35
An intravenous form of vitamin E,  α-tocopherol acetate, causes cholestatic jaundice
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primarily involving the canalicular duct in premature infants. The incidence of this
reaction in those receiving this formulation was high (>10%) and the mortality even
higher  (>50%).36 Hepatocellular  cholestasis  is  a  much  more  serious  form  of
cholestatic jaundice that involves both the parenchyma and bile canalicular cells. 
1.4.6  MIXED  HEPATOCELLULAR  NECROSIS  AND  CHOLESTATIC
DISEASE
Patients  infrequently  present  with  a  purely  hepatocellular  necrosis  or  cholestatic
damage, but rather with a mixed picture of damage. Flutamide causes a mix of lesions
that appear at or about the fortyeighth week of treatment.37 Niacin in doses greater
than 3 g/day, or in doses greater than 1 g/day of sustained-release formulations, cause
the same mixed pattern of damage.38 These patients often presen  with only a few
signs  or  symptoms at  first,  but  can  progress  rapidly to  fulminant  hepatic  failure.
Additionally, niacin-induced and other drug-induced mixed hepatocellular disease can
be misinterpreted as hepatobiliary cancers.39
1.4.7 NEOPLASTIC DISEASE
A large body of the current literature on adverse reactions and the liver addresses the
development of neoplasms following drug therapy. Both carcinoma- and sarcoma-like
lesions have been identified. Fortunately, hepatic tumors associated with drug therapy
are  usually  benign  and  remit  when  drug  therapy  is  discontinued.  Except  in  rare
instances,  these  lesions  are  associated  with  long-term  exposure  to  the  offending
agent.40 Androgens,  estrogens,  and  other  hormonal-related  agents  are  the  most
frequently  associated  causes  of  neoplastic  disease.  The  model  for  drug-induced
hepatic cancer is polyvinyl chloride exposure. Used in the production of many types 
of plastic products, polyvinyl chloride induces angiosarcoma in exposed workers after
as few as 3 years of exposure.41
1.5 ASSESSMENT
The best  and most important  technique for assessing and monitoring drug-induced
liver disease is the patient’s history. Questions addressing the patient’s drug use along
with a thorough review of systems are essential. The use of a protocol, such as that
proposed  by Danan  and  Benichou,  can  significantly  improve  the  accuracy of  the
assessment (Table 38–1).42 The use of drugs for recreational purposes must not be
overlooked.  Cocaine has  been directly linked to  liver  disease.43 Ecstasy,  the street
name of  methylenedioxymethamphetamine,  has  induced  fulminant  hepatitis  which
has led to death in some cases.44 The more pervasive impact of street drugs on the
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incidence of hepatic disease is the concomitant injection or ingestion of adulterants.
Many of these adulterants are either directly toxic or serve to enhance the toxicity of
the drug. It is also good to try to determine nondrug hepatic disease risk. Arsenic, for
example, is known to induce both acute and chronic hepatic reactions. Arsenic in low
concentrations is found in insectresistant lumber.45 Pennyroyal oil, maragosa oil, and
clove oil cause a dose-related hepatotoxicity.46,47 The nutritional status of a patient can
be as important to the development of a drug-induced liver disease as the hepatotoxin
itself.48 Patients who are malnourished because of illness or long-term alcohol abuse
make up the most troublesome group.50,49 Low serum levels of vitamins E and C along
with lutein and the α- and β-carotenes are associated with asymptomatic elevations in
transaminases. Conversely, high serum iron, transferrin, and selenium levels are also
associated with asymptomatic elevations of transaminases.51 All potential drug 
reactions should be judged as to the timing of the reaction versus drug administration,
pharmacokinetic  considerations,  Often  there  is  no  good  clinical  test  available  to
determine the exact type of hepatic lesion, short of liver biopsy.53,52 The specificity of
any serum enzyme depends on the distribution of that enzyme in the body. Alkaline
phosphatase is found in the bile duct epithelium, bone, and intestinal and kidney cells.
5_-Nucleotidase  is  more  specific  for  hepatic  disease  than  alkaline  phosphatase,
because  most  of  the  body’s  store  of  5_-nucleotidase  is  in  the  liver.  Glutamate
dehydrogenase  is  a  good  indicator  of  centrolobular  necrosis  because  it  is  found
primarily  in  centrolobular  mitochondria.  Most  hepatic  cells  have  extremely  high
concentrations  of  transaminases.  Aspartate  aminotransferase  (AST)  and  alanine
aminotransferase  (ALT)  are  commonly  measured.  Because  of  their  high
concentrations and easy liberation from the hepatocyte cytoplasm, AST and ALT are
very sensitive indicators of necrotic lesions within the liver. After an acute hepatic
lesion is established, it may take weeks for these concentrations to return to normal.54
Serum bilirubin concentration is a sensitive indicator of most hepatic lesions and has
significant prognostic value. High peak bilirubin concentrations are associated with
poor  survival.  Other  important  findings  that  indicate  poor  survival  are  a  peak
prothrombin time greater than 40 seconds, elevated serum creatinine, and low arterial
pH. The presence of encephalopathy or prolonged jaundice are not good signs for the
survival of the patient and are strong indicators for transplantation.55
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1.6 ISONIAZID AND RIFAMPICIN INDUCED HEPATOTOXICITY:
DILI may occur with all currently recommended regimens for the treatment of latent
TB infection (LTBI), including isoniazid for 6 to preferably 9 months, rifampin for 4 
months,  or  isoniazid  and  rifampin  for  4  months  56 This  is  also  true  of  two-drug
regimens of pyrazinamide with either ethambutol or a fluoroquinolone used to treat
contacts of multidrug-resistant (MDR) TB cases 57-59 Metabolic idiosyncratic reactions
appear to be responsible for most DILI from the first-line anti-TB medications and
fluoroquinolones.
1.6.1 Isoniazid
Metabolism.  Isoniazid is cleared mostly by the liver, primarily by acetylation by N-
acetyl transferase 2 (NAT-2). Acetyl-isoniazid is metabolized mainly to mono-acetyl
hydrazine  (MAH) and  to  the  nontoxic  diacetyl  hydrazine,  as  well  as  other  minor
metabolites  60 Interindividual  variation  in  plasma  elimination  halflife  (t1/2),
independent  of  drug  dose  and  concentration,  is  considerable.  Individuals  with
prolonged t1/2 have extended exposure to the drug. Genetic polymorphisms of NAT-2
correlate  with fast,  slow, and intermediate acetylation phenotypes  61-63 Microsomal
enzymes  (e.g.,  cytochrome  P450  2E1)  further  metabolize  isoniazid  intermediates
through phase 1 pathways.
Acetylator status. In fast acetylators, more than 90% of the drug is excreted as acetyl-
isoniazid, whereas in slow acetylators, 67% of the drug is excreted as acetyl-isoniazid
and a greater percentage of isoniazid is excreted as unchanged drug into the urine. The
influence of acetylation rate on isoniazid hepatotoxicity is controversial. Most studies
on this question involved patients on multidrug regimens for TB disease and relied on
phenotypic assays of acetylation, which can be imprecise.  Fast acetylators may be
misidentified as slow if they exhibit delayed drug absorption during blood sampling at
limited time points. Early studies suggested that fast acetylators were at higher risk for
hepatic injury because they generated more acetyl-isoniazid, which could be further
metabolized to other toxic intermediaries 64,65,66 However, fast acetylators clear MAH
more rapidly. Slow acetylators may actually have greater cumulative MAH exposure.
Increased  susceptibility  among  slow  acetylators  67 or  a  lack  of  correlation  with
acetylation rate has been reported 68 NAT-2 genotyping by polymerase chain reaction
recently  demonstrated  that  slow acetylators  experience  transaminase  elevations  of
more than three times the ULN more frequently than rapid acetylators (26 vs. 11%).
Slow  acetylators  also  had  higher  peak  ALT  than  did  fast  acetylators  and,  when
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rechallenged with isoniazid, more frequently developed transaminase elevation of at
least three times the ULN. The significance of these findings awaits further studies. 
Mechanism of injury.  Reactive metabolites  of MAH are probably toxic to tissues
through free radical generation. In rats, the free radical scavenger glutathione-related
thiols, and antioxidant glutathione peroxidase and catalase activities, are diminished
by isoniazid, although glutathione reductase activity is increased 69,70 The antioxidant
N-acetyl-cysteine,  a  substrate  for  glutathione  synthesis,  inhibits  isoniazid-induced
liver  injury  in  pretreated  rats,  with  unknown  relevance  in  humans.  Additional
metabolic idiosyncratic mechanisms appear to be operative. The isoniazid metabolite
acetyl-hydrazine covalently binds to  liver  macromolecules,  a  process  mediated  by
microsomal enzymes. Patients with homozygous cytochrome P450 2E1 c1/c1 host
gene polymorphism, who have enhanced cytochrome P450 2E1 activity, in one study
had a higher risk of hepatotoxicity, particularly in slow acetylators.
Histopathology. Nonspecific changes resemble those of viral hepatitis with nonzonal
necrosis, and are massive in up to 10% of severe cases. Subacute hepatic necrosis can
be seen in 30% of cases 71
Drug interactions. Isoniazid inhibits the activity of several cytochrome P450 2E and
2C enzymes,  potentially increasing the  plasma concentrations  of  other  potentially
hepatotoxic drugs,  such as  phenytoin and carbamazepine  72-74 Rifampin appears to
enhance  a  metabolic  hepatocellular  idiosyncratic  reaction  in  patients  receiving
isoniazid, perhaps by promoting the formation of toxic isoniazid metabolites 75,76
Hepatic  adaptation. Up to 20% of individuals treated with isoniazid alone for LTBI
may experience low-grade, transient, asymptomatic transaminase elevation, most of
which represents hepatic adaptation 77
Clinical  presentation  of  hepatotoxicity.  Some  individuals  may  be  asymptomatic,
whereas  others  may  experience  symptomatic  hepatotoxicity  at  varying  serum
transaminase concentrations. Constitutional symptoms may be seen early in severe
hepatotoxicity, and may last from days to weeks. Nausea, vomiting, and abdominal
pain are seen in 50 to 75% of patients with severe illness, whereas fever is noted in
10% and rash in 5% of patients. Overt jaundice, dark urine, and clay-colored stools
are  late  signs  of  clinical  worsening.  Coagulopathy,  hypoalbuminemia,  and
hypoglycemia signify life-threatening hepatic dysfunction. The regression of isoniazid
hepatotoxicity  usually  takes  weeks.  Recovery  is  complete  in  most  after
discontinuation of isoniazid.
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Overall  rates  of  hepatotoxicity.  Initial  experience  with  isoniazid  up  to  the  1960s
indicated the rates of treatment-limiting adverse events were similar in placebo- and
isoniazid-treated  groups,  except  for  gastrointestinal  complaints  78  with  hepatitis
occurring relatively rarely. In the late 1960s, isoniazid’s ability to cause asymptomatic
elevations in hepatic transaminases and clinically significant hepatitis was recognized.
In 1970, 19 of 2,321 Capitol Hill workers treated with isoniazid developed clinical
signs  of  liver  disease  and two died of  resulting complications  79 The U.S.  Public
Health Service (USPHS) surveillance study 80 of 14,000 isoniazid-treated individuals
found an overall rate of significant, probable isoniazid hepatitis of 1%, with a cluster
of  seven  of  eight  reported  deaths  in  one  city.  A subsequent  study,  using  passive
detection, by the International Union Against Tuberculosis (IUAT), found the overall
rate of hepatitis in patients receiving up to 12 months of isoniazid was 0.5 versus
0.1%  receiving  placebo  81 From  the  1970s  to  the  1990s,  isoniazid-related
hospitalization rates declined from as much as 5.0 per 1,000 treatment initiations to
0.1 to 0.2 (median, 0.15), and mortality rates fell from as high as 1.0 per 1,000 to 0–
0.3 per 1,000 (median, 0.04)  82,83 These declines may have been related to careful
patient selection, education, and active monitoring for adverse reactions to isoniazid 85
A study of isoniazid for treatment of LTBI, involving more than 11,000 patients in
Seattle–King County, Washington, reported that symptomatic transaminase elevation
of more than five times the ULN occurred in 0.1% of treatment initiations 86 Routine
follow-up transaminase monitoring of asymptomatic individuals was not done in this
clinic,  which  the  authors  estimated  could have  raised  the incidence  of  significant
transaminase  elevation  into  the  range  of  older  studies,  to  approximately  0.6%.
Hepatotoxicity rates could also have been higher if based on those patients actually 
taking  medication,  rather  than  on  treatment  initiations.  The  study  generally
demonstrated a relatively low risk of isoniazid hepatotoxicity within the context of a
TB program providing patient education, specific instructions about adverse events,
and monthly clinical observations. A subsequent study of 3,788 patients treated for
LTBI with isoniazid in San Diego, California, reported that transaminase elevations of
three  times  the  ULN  in  symptomatic  individuals  and  five  times  the  ULN  in
asymptomatic individuals occurred in 0.3% of cases 87 
Age. Most isoniazid-associated hepatotoxicity is age associated. The Seattle study of
symptomatic transaminase elevation showed ranges from 0% in those younger than
14 years  to  0.28% in those  older  than  65.  The San Diego  study reported  a trend
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toward age-related hepatotoxicity,  with only 15% of the study population aged 35
years or older. The Tennessee study reported that age-specific AST elevation more
than five times the ULN ranged from 0.44% in those younger than 35 years to 2.08%
for those older  than 49 years  88 a  statistically significant difference.  In  comparing
these studies, 20% of the more than 11,000 patients in the Seattle study population
were  at  least  35  years  old,  compared  to  59%  in  the  USPHS  and  54.6%  in  the
Tennessee studies. Sample sizes for this age group were comparable in the Seattle (n _
2,228) and the Tennessee studies (n _ 1844). Differences in the findings among these
studies may be attributed to differing definitions of hepatotoxicity, patient selection,
and  in  ability  to  exclude  confounding  causes  of  hepatotoxicity.  The  severity  of
isoniazid-related hepatitis  has been reported to also increase with age,  with higher
mortality in those older than 50 years 89,90
Racial differences.  In  theUSPHS study, African-American males appeared to have
less risk of DILI than white males, but there was no difference for women of any race.
Asian males appeared to have nearly double the rate of probable isoniazid hepatitis
than white males and nearly 14 times that of black males. In the Seattle–King County
study,  there  was  a  nonsignificant  trend  toward  higher  hepatotoxicity  in  white
individuals,  without  other  significant  racial  differences.  The  Memphis,  Tennessee,
study  found  no  associations  among  racial  groups  or  demographic  subgroups  and
hepatotoxicity. There do not appear to be consistent racially based risks for high-grade
hepatotoxocity.
Sex. There is currently no clear evidence to point to an overall sex-related difference
in the incidence of hepatotoxicity. Pregnant women in the third trimester and in the
first 3 months of the postpartum period may be at higher risk for the development of
hepatitis 91 In the USPHS study, there was no overall difference between women and
men in  rates  of  probable  isoniazid hepatotoxicity.  The Seattle–King County study
found a nonsignificant trend toward higher isoniazid-related hepatotoxicity in women
compared with men, although the incidence of severe hepatotoxicity was relatively
low  in  both  men  and  women.  The  Memphis  and  San  Diego  studies  found  no
significant associations between sex and hepatotoxicity 
Deaths.  Several  retrospective  studies  and  reviews  with  methodologic  limitations
suggest that the severity of isoniazidinduced hepatotoxicity, when it does occur, may
be worse in women. In the USPHS study there were 8 deaths among 13,838 enrolled
subjects (0.57 per 1,000 treated), 5 of which were in African-American women, with
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7 of 8 deaths occurring in Baltimore, Maryland. Most of those who died had potential
cofactors  for  hepatotoxicity,  including  severe  alcoholism  or  ingestion  of  other
hepatotoxic  drugs.  Another  cofactor  may  have  been  involved  in  the  observed
clustering, as a subsequent review of death certificates showed a surge in cirrhosis-
related deaths in Baltimore and surrounding counties during the time period of this
study 92 In the IUAT study, there were three deaths with a death rate of 0.14 of 1,000
treated. A review of probable and possible isoniazid hepatitis cases from 1970 to 1992
suggested a case fatality rate of 0.042 per 1,000 persons beginning therapy and a rate
of no greater than 0.07 per 1,000 persons completing therapy. This review included
some of  the  previously discussed  fatalities.  There  were  62  probable  and  possible
isoniazid hepatitis deaths, 50 (81%) of the patients were female, and 49 (79%) were
non-Hispanic black or Hispanic. Although most individuals who died were older than
35 years, a surprising 31% were younger. Although these are numerator data only,
they indicate that  no age group is free of risk.  Another review of fatal cases also
suggested that women may be at higher risk for death from isoniazid-related hepatitis.
Cofactors.  In the USPHS surveillance study, alcohol consumption appeared to more
than double the rate of probable isoniazid hepatitis, with daily consumption increasing
the rate more than four times. Transaminase elevation may be, in some cases, related
to chronic  ethanol  use.  Hepatotoxicity during concomitant  administration  of  other
hepatotoxic  drugs,  such  as  acetaminophen  93,  methotrexate  94,  sulfasalazine  95,  or
carbamazepine 95, as well as others, has been reported.
HIV-infected individuals.  HIV-infected individuals appear to experience isoniazid-
related hepatotoxicity in the same range as HIV-uninfected individuals 96, although no
direct comparisons through clinical trials have been done.
Hepatitis  C.  Two  studies  showed  no  independent  isoniazid  hepatotoxicity  risk
associated  with  hepatitis  C  infection.  In  Baltimore,  Maryland,  a  cohort  of  146
tuberculin skin test–positive injection-drug users, 95% of whom were infected with 
hepatitis C, with baseline serum transaminase concentrations less than three times the
ULN, and 25% of whom were HIV infected, received isoniazid for LTBI. Observed
with  monthly  blood  tests,  32  patients  (22%)  had  increased  transaminase
concentrations to more than five times the ULN. Abnormal results were associated
with  alcohol  use,  but  not  with  race,  age,  chronic  hepatitis  B  infection,  or  HIV
infection.  Both the rate  of  hepatitis  and the rate  of  isoniazid discontinuation were
within  the  historical  range  for  populations  with  a  low  prevalence  of  hepatitis  C
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infection (10 to 22% and 0.1 to 10%, respectively). A second study in Spain found
that only excessive alcohol consumption and a high baseline ALT concentration were
independently associate  with isoniazid hepatotoxicity.  The presence  of  hepatitis  C
virus (HCV) antibody was associated with hepatotoxicity only on univariate analysis
in this study.
Elevated  baseline  transaminases.  The Tennessee  retrospective  study found  that  a
baseline AST greater than the ULN was a risk factor for developing transaminase
elevation greater than five times the ULN, as did another study among intravenous
drug users.
Other factors increasing frequency or severity of hepatotoxicity.
Concomitant  treatmentwith  rifampin,malnutrition,  prior  isoniazidrelated
hepatotoxicity, and continued use of isoniazid while symptomatic have been described
to contribute to higher-grade isoniazid hepatotoxicity. 
1.6.2 Rifampin
Rifampin,  and  similarly  rifapentine,  may  occasionally  cause  dosedependent
interference  with  bilirubin  uptake,  resulting  in  subclinical,  unconjugated
hyperbilirubinemia or jaundice without hepatocellular damage. This may be transient
and occur early in treatment or in some individuals with preexisting liver disease 90-92
Rifampin occasionally can cause hepatocellular injury and potentiate hepatotoxicities
of other anti-TB medications 93,94 In a study of patients with brucellosis treated with
the combination of rifampin and minocycline, rifampin-attributed ALT increases of at
least 250 IU/L were seen in approximately 5% of patients  95. In two small series of
patients  with  primary  biliary  cirrhosis,  in  whom  baseline  transaminases  were
significantly elevated, clinically significant hepatitis was attributed to rifampin in 7.3
and 12.5% of patients 96,97. 
Mechanisms of hepatotoxicity. Conjugated hyperbilirubinemia probably is caused by
rifampin  inhibiting  the  major  bile  salt  exporter  pump  98.  Asymptomatic  elevated
bilirubin  may  also  result  from  dose-dependent  competition  with  bilirubin  for
clearance at the sinusoidal membrane or from impeded secretion at the canalicular
level 99,100. Rare hepatocellular injury appears to be a hypersensitivity reaction, and it
may be more common with large, intermittent  doses  101.  Hypersensitivity reactions
have  been  reported  in  combination  with  renal  dysfunction,  hemolytic  anemia,  or
“flulike syndrome” 102,103.
Department of pharmacology                                                                                                                                            Page 26
Drug interactions. Rifampin activates hepatotocyte pregnane X receptors, leading to
induction of cytochromes. Rifampin also induces uridine diphosphate-glucuronosyl-
transferases and P-glycoprotein transport, which are involved in the metabolism of
other drugs104-108 Rifampin interacts with numerous drugs metabolized by these and
other  hepatic  enzymes,  including  warfarin,  prednisone,  digitoxin,  quinidine,
ketoconazole,  itraconazole,  propranolol,  clofibrate,  sulfonylureas,  phenytoin,  HIV
protease inhibitors, and HIV nonnucleoside reverse transcriptase inhibitors109. 
Clinical characteristics of hepatotoxicity. Cholestasis may be insidious. Idiosyncratic
hypersensitivity  reaction  to  rifampin,  manifested  as  anorexia,  nausea,  vomiting,
malaise, fever, mildly elevated ALT, and elevated bilirubin, usually occurs in the first
month of treatment initiation110. 
Overall  hepatotoxicity.  Four  published  TB-related  studies  have  assessed  rifampin
alone  for  treatment  of  LTBI.  In  a  study  by  the  Hong  Kong  Chest  Service,
transaminase elevations above the ULN were more common among patients receiving
isoniazid- containing regimens than they were among the 77 of 172 patients treated
with  rifampin  alone  who  had  follow-up  liver  enzyme  analyses.  There  was  no
significant difference between the geometric means of serum ALT for the placebo and
rifampin groups. In the second study111,  none of the 49 individuals, 20% of whom
used  alcohol  and  8% of  whom used  injection  drugs,  treated  with  rifampin  for  6
months  had symptomatic liver  injury.  There  was no assessment  for  asymptomatic
transaminase  elevations.  Among  157  adolescents  treated  with  rifampin,  4  (2.5%)
developed  ALT elevations  at  least  two  times  the  ULN,  for  which  treatment  was
permanently  discontinued  in  one112,113.  A  randomized  study  of  isoniazid  versus
rifampin for treatment of LTBI in Montreal, Canada, found that, among 53 patients
who completed 80% of a 4-month course of rifampin for LTBI, none experienced
significant transaminase elevation. The apparent low rate of hepatotoxicity observed
in these limited studies awaits confirmation in larger prospective studies.
Isoniazid and Rifampin
A Canadian study found that rates of hepatitis were similar for patients treated with
intermittent  isoniazid  and  rifampin  compared  with  historical  control  subjects
receiving daily isoniazid for 12 months. The rate of symptomatic hepatitis with the
combination of isoniazid and rifampin has been estimated at 2.55% in a meta-analysis
that included patients with TB disease, a higher incidence than in regimens containing
one or the other drug114.
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AIM &OBJECTIVE 
                    Aims:  Herbal medicines have recently attracted much attention as
alternative medicines useful for treating or preventing life style related disorders and
relatively very little knowledge is  available about their mode of action. There has
been a growing interest in the analysis of plant products which has stimulated intense
research on their potential health benefits-116. Therefore present study was designed to
Evaluate  Hepatoprotective  activity  of  ethanolic  extract  of  polygonum glabrum on
hepatoxicity induced by anti-tubercular drugs like INH and rifampicin in rats.
2.2 OBJECTIVES OF THE STUDY:
1. To prepare ethanolic extract of Polygonum glabrum
2. To  study  the  phytochemical  screening  of  ethanolic  extract  Polygonum
glabrum
3. To study the acute oral toxicity ethanolic extraction of Polygonum glabrum
4. To  study  the  hepatoprotective  activity  of  ethanolic  extract  of  Polygonum
glabrum in rats
5. To carry out histopathological studies.
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Muddathir AK,et.al., Reported Anthelmintic properties of Polygonum glabrum.
They  isolated  a pure  anthelmintic  substance  (PGA)  from  the  methanol-aqueous
extract of the leaf of Polygonum glabrum Willd., a semi-aquatic Sudanese species of
the  family  Polygonaceae.  The  antiparasitic  in-vitro  activity  of  several  fractions
isolated from the plant, has been examined comparatively with that of PGA. PGA also
showed molluscicidal activity against Biomphalaria glabrata and Limnea truncatula
Müll. Structural determination of PGA was attempted following data analysis of UV,
IR, 13C NMR, 1H NMR and MS spectra and suggests that PGA is a terpenoid.
Sinha P,et.al.,Reported Pharmacognostic studies on leaf of Polygonum glabrum Willd.
has been carried out along with its numerical values, fluorescence characteristics and
ash and extractive values.
Muddathir AK, Balansard G, Timon-David P, Babadjamian A, Yogoub AK, Julien MJ.
Anthelmintic properties of Polygonum glabrum.J Pharm Pharmacol. 1987 
Apr;39(4):296-300. 
SinhaP, KumarA, WahiSP.Pharmacognostical studies on leaf 
of polygonum glabrum willd. Anc Sci Life. 1986 Jul;6(1):13-9.
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PLANT PROFILE
Plant Profile
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Botanical Name:      Polygonum glabrum Willd
Scientific Classification
Kingdom          :      Plantae
Subkingdom     :      Tracheobionta
Class                 :      Magnoliopsida 
Order                :      Polygonales
Family             :       Polygonaceae
Genus              :       Polygonum   L.
Species           :Polygonum   glabrum   Willd. 
Synonyms :
Polygonum densiflorum, Polygonum portoricense, Persicaria glabra
Common Name : 
English : Common Marsh Buckwheat
Vernacular Name:
India (Santal): Sauri arak, Jioti.  
Balrampur, Oudh :Larboma, Bih langani bonka.
Assam: Patharua,
Bombay:Rakta rohia,
Tamil: Actalaree, Sivappu Kumbakodaali,
                Mangalore : Neeru kanagilu1,
                Malayalam: Chuvanna mudela mukkum,
Bengali: Bihagni, Sada Kukri.  
Habit: An annual herb.
Habitat and Distribution:
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 Common, grows gregariously in marshy areas, Plains from the coast to 1400m. India,
Nepal,  Sri  Lanka,  Pakistan,  Java,  South  China,  Africa,  Afghanistan,  South Japan,
Malaysia, Sylhet, Chittagong; in ditches and swamps. In India: Karnataka, Gujarat,
Madhya Pradesh, Maharashtra, Orissa, Punjab, Rajasthan, Sikkim, Uttar Pradesh and
West Bengal.
Description:
                         Polygonum glabrum Willd - An erect annual, with reddish stem, 0.6-
1.5 m long procumbent  and usually reddish below, shrubby,  ochreas membranous,
glabrous, lowers in terminal and axillary spike like racemes, perianth rose or red. Nuts
are dark brown and shiny. Leaves are of 7.5-23 cm long, lanceolate, finely acuminate;
stipules  2.2-3.2  mm  long,  those  on  the  old  stem  torn,  when  young  completely
sheathing  the  stem,  the  mouth  truncate,  not  ciliate.  Flowers  are  pink,  small,  in
paniculate slender racemes. The plant mostly found in river banks, stream sides and
marshy areas. It is found as dense clumps and is sub shrubs and growing up to 2.5 cm.
The young shoots and roots are cooked with vegetables.
Chemical constituents:
The phytochemical screenings of chloroform extract shows the presence of chemical
compounds like alkaloid, carbohydrates, flavonoids and methanol extract shows the
presence  of  alkaloids,  flavonoids,  and  phenolic  compounds.  The  chromatographic
studies shows various spots (Paper/Hptlc) with chloroform extract may confirm the
presence of alkaloid contents in the plant. The spectral studies like U.V and FTIR are
the preliminary work for the detection of some alkaloidal contents in the plant. Aerial
parts contain a number of biologically active terpenoids and flavones. Leaves contain
flavonoids like quercetin, rhamnetin, quercitrin, avicularin and rutin. Stem and seeds
contain  vanillic  acid,  syringic  acid, p-hydroxybenzoic  acid,  protocatechuic  acid,
Gallic acid and coumaric acid, kaempferol-3-methyl ester, quercetin and hyperin
Medicinal uses:
                A good number of species Polygonum have been used traditionally from a
long  time  for  a  number  of  ailments  in  the  indigenous  system  of  medicine.  The
medicinal  properties  attributed  to  the  species  of  Polygonum  are  demulcent  and
pectoral,  astringent  and  tonic,  diuretic,  emetic,  purgative,  febrifuge,  vesicant,
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vulnerary,  insecticide  and  anthelmintic  117 Besides  it  also  possess  antiviral  118 and
antibacterial 119 properties. The root stocks are reported to be used in piles, jaundice,
debility and consumption. The herb possess antibacterial activity against micrococcus
pyrogens  and  diplococcus  pyrogens.  Some  naturally  occurring  flavonoids  like
kaemphferol-3-methyl ester, quercetrin, quercetin shows antifungal activity. But fresh
juice of the leaves possesses poisonous properties 
Pharmacological activities:
Polygonum glabrum has been mentioned in Ayurveda and is known as Rasna, though
its clinical use does not appear to include nervous disorders. It has been studied for its
anti-inflammatory  120 and  antidepressant  121 properties.  The  findings  show  that
Polygonum  glabrum  extract  is  clinically  effective  as  anti-inflammatory  drug  and
works  by the  mechanism of  action similar  to  that  of  NSAIDs.  PG also has  been
researched for anthelmintic activity  122, which showed activity against  Hymenolepis
nana var.  fraternal.  PG contains several compounds of biological interest, including
the sesquiterpenes, a broad spectrum of flavanoids 123 and polyphenols 124. 
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                                      MATERIALS AND METHODS  
Materials: 
Chemicals and reagents
Serum parameters were estimated using analysis kits purchased Robonik diagnostics
Pvt Ltd, Navi Mumbai, India (SGOT, SGPT, TP and Bilirubin) and. Silymarin was a
gift  from Micro  Labs,  Hosur,  Tamil  Nadu,  India.  Rifampicin  and  Isoniazide  were
obtained from Lupin Ltd., Mumbai, India; anaesthetic ether was from TKM Pharma,
Hyderabad, India; and ethanol and chloroform were from Rankem Ltd, New Delhi,
India.
Diagnostic kits:  
Diagnostic kits  used for estimation of,  SGOT, SGPT, ALP, Total protein, bilirubin
were procured from Robonik Pvt Limited.
Instruments: 
Autoanalyzer  (Robonik),  Refrigerator  centrifuge  (MPW-350R),UV-
Spectrophotometer  (UV-1601, Shimadzu Corporation, Kyoto,  Japan),  Mini Lyotrap
(LTE  Scientific  Ltd.),  Research  centrifuge  (Remi  industries,  Mumbai)  and
homogenizer (Remi Motors, Mumbai). Dhona balance (M/S Dhona instruments Pvt.
Ltd., Kolkata, India).
Plant material and extraction
The bark of  Polygonum glabrum Willd plant  was collected during the march 2013
from  Sri Venkateshwara University, Tirupati, India. The plant was authenticated by
Dr. Madhava Chetty, Department of Botany and voucher specimen of the plant were
preserved at institute herbarium library. Bark was separately washed, wiped-dry, and
subsequently reduced to a coarse powder. About 100 g of the bark were separately
extracted for 24 h with 75% ethanol with intermittent vigorous shaking. The extracts
were filtered, concentrated with a rotary evaporator and dried over a water bath at
45°C. The residue from the plant parts were used for experimental analysis125.
PRELIMINARY PHYTOCHEMICAL STUDIES126
Ethanolic  extract  of  the  plant  of  Polygonum glabrum Willd were  subjected  to
chemical tests for the identification of their active constituents.
Tests for carbohydrates and glycosides
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A small quantity of the extract was dissolved separately in 4 ml of distilled water and
filtered.   The  filtrate  was  subjected  to  Molisch’s  test  to  detect  the  presence  of
carbohydrates.
A. Molisch’s Test
Filtrate was treated with 2-3 drops of 1% alcoholic α-naphthol solution and 2ml of
con. H2SO4 was added along the sides of the test tube. Appearance of violet coloured
ring  at  the junction of  two liquids  shows  the presence  of  carbohydrates.  Another
portion of the extract was hydrolysed with HCl for few hours on a water bath and  the
hydrolysate was subjected to Legal’s and Borntrager’s test to detect the presence of
different glycosides.
B. Legal’s Test: 
To the hydrolysate, 1ml of pyridine and few drops of sodium nitroprusside solution
were  added  and  then  it  was  made  alkaline  with  sodium  hydroxide  solution.
Appearance of pink to red colour shows the presence of glycosides.
C.  Borntrager’s  Test: Hydrolysate  was  treated  with  chloroform  and  then  the
chloroform layer was separated.  To this equal quantity of dilute ammonia solution
was  added.  Ammoniacal  layer  acquires  pink  colour  showing  the  presence  of
glycosides.
4.2.4  Tests  for  alkaloids: A small  portion  of  the  methanol  extract  was  stirred
separately with few drops  of  dil.  HCl  and filtered.   The filtrate  was  treated  with
various reagents as shown for the presence of alkaloids.
Mayer’s reagent             -   Creamy precipitate 
Dragandroff’s reagent         -   Orange brown precipitate 
Hager’s reagent            -    Yellow precipitate 
Wagner’s reagent            -     Reddish brown precipitate
4.2.5 Tests for phytosterol
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The extract was refluxed with solution of alcoholic potassium hydroxide till complete
saponification takes  place.  The mixture was diluted and extracted with ether.  The
ether layer was evaporated and the residue was tested for the presence of phytosterol.
Libermann Burchard Test:
The residue was dissolved in few drops of acetic acid, 3 drops of acetic anhydride was
added followed by few drops of con. H2SO4.  Appearance of bluish green colour
shows the presence of phytosterol.
4.2.6 Tests for fixed oils
Spot test:
Small  quantity  of  extract  was  separately  pressed  between  two  filter  papers.
Appearance of oil stain on the paper indicates the presence of fixed oil. Few drops of
0.5N alcoholic potassium hydroxide were added to a small quantity of extract along
with a drop of phenolphthalein.  The mixture was heated on water bath for 1-2 hours.
Formation of soap or partial neutralization of alkali indicates the presence of fixed
oils and fats.
 4.2.7 Tests for gums and mucilages:
Small quantity of the extract was added separately to 25 ml of absolute alcohol with
constant stirring and filtered. The precipitate was dried in air and examined for its
swelling properties for the presence of gums and mucilages.
4.2.8 Tests for Saponins:
The extract was diluted with 20 ml of distilled water and it was agitated in a graduated
cylinder for 15 minutes.  The formation of 1cm layer of foam shows the presence of
saponins.
4.2.9 Tests for proteins and free amino acids:
Small  quantity  of  the  extract  was  dissolved in  few ml  of  water  and  treated  with
following reagents.
A. Millon’s reage Appearance of red colour shows the presence of protein   and free
amino acids.
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B.  Ninhydrin reagent - Appearance of purple color shows the presence of   proteins
and free amino acids.
C.   Biuret  test  -  Equal  volumes  of  5%  NaOH solution  and  1% copper  sulphate
solution were  added.  Appearance of  pink or  purple  colour  shows the presence of
proteins and free amino acids.
4.2.10 Tests for phenolic compounds and tannins
Small quantity of the extract was taken separately in water and tested for the presence
of phenolic compounds and tannins using following reagents.
A. Dil.FeCl3 solution (5%)                                                 -violet colour
B. 1% solution of gelatin containing 10% NaCl               - white precipitate
C. 10% lead acetate solution                                                - white precipitate.
4.2.11 Tests for flavonoids
A. With aqueous Sodium hydroxide solution:
Blue  to  violet  colour  (anthocyanins),  yellow  colour  (flavones),  yellow  to  orange
(flavonones)
B. With Con. H2SO4:
Yellow orange colour (anthocyanins), yellow toorange colour (flavones),  orange to
crimson (flavonones)
C. Shinoda’s test
Small  quantity  of  the  extract  was  dissolved  in  alcohol  and  to  that  a  piece  of
magnesium followed by Con. HCl drop wise was added and heated.  Appearance of
magenta colour shows the presence of flavonoids.
The results of preliminary phytochemical studies of the plant extract are presented in 
Table1.  Phytochemical  screening of  methanolic  extract  of  Polgonum glabrum
Willd.
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Phytoconstituents Presence or Absence
AbsentCarbohydrates +
Glycosides +
Fixed oils and fats -
Gums & mucilage -
Potein & amino acids +
Saponins +++
Tannins +
Phytosterols ++
Flavonoids ++
Alkaloids +++
6 Experimental Animals:
Wistar albino male rats (180–220 g) was obtained from the central animal house of
Sigma  Institute  of  Clinical  Research  and  administration  Pvt  Ltd  Hyderabad.  The
animals were housed at room temperature (22-28 ºC) for 12 hr dark and 12 hr light
cycle  and  given  standard  laboratory  feed  and  water  ad-libitum.  The  study  was
approved  and  conducted  as  per  the  norms  of  the  Institutional  Animal  Ethics
Committee (769/2010/CPCSEA).
Acute oral toxicity study 
Procedure:
 Acute toxicity studies were performed according to OECD-423 guidelines category
IV substance (acute toxic class method). Albino mice (n=3) of either sex selected by
random sampling technique were employed in this study. The animals were fasted for
4  hrs  with  free  access  to  water  only.  The  Polygonum glabrum Willd,  India  were
administered orally with a maximum dose of 2000 mg/kgbody weight. The mortality
was observed for three days. If mortality was observed in 2/3 or 3/3 of animals, then
the dose administered was considered as a toxic dose. However, if the mortality was
observed only one mouse out of three animals then the same dose was repeated again
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to confirm the toxic effect.  If  mortality was not observed, the procedure was then
repeated with higher dose (Organization for economic Co-operation and development,
2001)127
Observations 
Animals were observed individually at least once during the first 30 minutes after
dosing, periodically during the first 24 hours (with special attention given during the
first  4  hours)  and  daily  thereafter,  for  a  total  of  14  days.  All  observations  were
systematically recorded with individual records being maintained for  each animal.
Observations  included  changes  in  skin,  mortality  and general  behavioural  pattern.
Attention was given for observations of tremors, convulsions, salivation, diarrhoea,
lethargy, sleep and coma. No death was observed till the end of study.
HEPATOPROTECTIVE ACTIVITY
Experimental design
Healthy  Albino  Wistar  male  rats  weighing  180-220  g  were  used.  They  were
randomized into 5 groups of 6 animals each as follows:
Group I: Normal received the vehicle viz. normal saline (2 ml/kg). 
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Group  II: Controls Received RCIN and INH (100 +50 mg/kg p.o.)[5] at every 72 h
for 21 days.
Group  III: Received  silymarin  50  mg/kg  p.o.  for  21  days  and  simultaneously
administered RCIN and INH (100 +50 mg/kg p.o.) every 72 h.
Group  IV: Received  MPG  200  mg/kg  p.o  for  21  days  and  simultaneously
administered a RCIN and INH (100 +50 mg/kg p.o.) every 72 h. 
Group  V: Received  MPG  400  mg/kg  p.o.  for  21  days  and  simultaneously
administered RCIN and INH (100 +50 mg/kg p.o.) every 72 h.
At the end of all experimental methods, all the animals were sacrificed by cervical
decapitation. Blood samples were collected, allowed to clot. Serum was separated by
centrifuging at 2500 rpm for 15 min and analyzed for various biochemical parameters.
The separated serum was used for the estimation of total bilirubin, direct bilirubin,
SGOT,  SGPT,  ALP  and  total  proteins  (TP).  The  animals  were  sacrificed  by
administering an excess of ether and their livers were removed.
Assessment of liver function: 
Biochemical  parameters  i.e.,  aspartate  amino  transferase  (AST)128 alanine  amino
transferase(ALT)128,  alkaline  phosphatase  (ALP)129,   total  bilirubin130 and  total
protein131   were analyzed according to the reported methods. The liver was removed,
weighed and morphological changes were observed. A 10% of liver homogenate was
used for antioxidant studies such as lipid peroxidation (LPO)132, superoxide dismutase
(SOD)133, catalase134. 
Histopathological studies: 
Liver  slices  fixed  for  12  hrs  in  Bouin’s  solution  were  processed  for  paraffin
embedding following standard micro techniques (18). 5µm sections of liver grained
with  alum  haematoxylin  and  eosin  were  observed  microscopically  for
histopathological changes.
Biochemical Estimation
SGOT/AST135
Principle 
Kinetic determination of the aspartate aminotransferase (GOT) activity : 
                                                              GOT
L - Aspartate + α – Ketoglutarate                             Oxaloacetate + L-Glutamate
                                                      MDH
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Oxaloacetate + NADH + H                                   L-Malate + NAD
  Assay procedure 1: Two Reagent procedure
Pipette in to test tubes Sample/Control
R1 800µl
R2 200 µl
Mix and Incubate at 37°C for 2 minutes then add
Pipette in to test tubes Sample/Control
Working reagent 1000µl
Sample/Control 100 µl
Mix and after a 60 seconds incubation at 37°C measure the change of absorbance per 
minute (∆A/minute) during 180 seconds.
Calculation :
Activity of Sample (U/L) = ∆ A/Min X 1746
SGPT/ ALT136
Principle 
Kinetic determination of the GPT activity
                                                            GPT
L - Alanine + α – Ketoglutarate                                   Pyruvate + L-Glutamate
                                                 LDH
Pyruvate + NADH + H+                                L-Lactate + NAD+
ASSAY PROCEDURE 1:  Two Reagent procedure
Pipette in to test tubes Sample/Control
R1 800µl
R2 200 µl
 Mix and Incubate at 37°C for 2 minutes then add
Pipette in to test tubes Sample/Control
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Working reagent 1000µl
Sample/Control 100 µl
Mix and after a 60 seconds incubation at 37°C measure the change of absorbance per 
minute (∆A/minute) during 180 seconds.
Calculation:
Activity of Sample (U/L) = ∆ A/Min X 1746
ALKALINE PHOSPHATASE137
p-Nitrophenyl  phosphate  is  converted  to  p-nitrophenol  and  phosphate  by alkaline
phosphatase. The rate of formation of p-Nitrophenol is measured as an increase in
absorbance  which  is  proportional  to  the  ALP  activity  in  the  sample.
ALP
p-Nitrophenyl phosphate                          p-Nitrophenol + Phosphate
Assay procedure 1: Two Reagent procedure
Pipette in to test tubes Sample/Control
R1 800µl
R2 200 µl
Mix and Incubate at 37°C for 2 minutes then add
Pipette in to test tubes Sample/Control
Working reagent 1000µl
Sample/Control 100 µl
Mix and after a 60 seconds incubation at 37°C measure the change of absorbance per
minute (∆A/minute) during 180 seconds.
Calculation:
At 405 nm with mono reagent procedure and two reagent procedure for 1 cm path
light cuvette
Activity of Sample (U/L) = (∆ A/Min) X 2712
TOTAL PROTEIN138 
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Proteins  together  with  copper  ions  form  a  violet  blue  color  complex  in  alkaline
solution.The absorbance of the color is directly proportional to the concentration.
Proteins + Cu                                   Colored complex
Assay procedure 
Pipette  in  to  test
tubes
Blank Standard Sample
Working reagent 1 1000 µl 1000 µl 1000µl
Distill water 20µl ……… ……..
Standard ……… 20 µl ……..
Sample ………. ……… 20 µl
Mix  and  read  the  absorbance  (A)  after  10  minutes  of  incubation  but  within  60
minutes.
Calculation:
                                         Concentration of Standard
Conc. of unknown Sample =                                  x Abs. of unknown Sample – Abs. 
of Reagent Blank
                                 Abs. Standard – Abs. of Reagent Blank
BILIRUBIN TOTAL & DIRECT139
PRINCIPLE:
In the determination of total bilirubin, bilirubin is coupled with diazotized sulphanilic
acid in the presence of caffeine benzoate solution to produce azobilirubin which has
maximum  absorbance  at  546  nm.  Direct  Bilirubin  in  presence  of  diazotized
sulphanilic acid forms a red coloured azo compound in acidic medium which has
maximum absorbance at 546 nm.
Assay procedure: 1 - Total Bilirubin End Point (Differential)
Sample  Blank  /  Control
Blank
Sample/ Control
Reagent R1 100 µl 100 µl 
Reagent R2                     — 50 µl
Reagent R3 1000 µl 1000 µl
Sample / Control 100 µl 100 µl 
Mix, let stand at room temperature for 5 minutes and read the absorbance of sample
against the sample blank.
Calculation: 
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Concentration in Sample (mg/dl) = (Abs. of Sample – Abs. of Sample Blank) X 14
(mg/dl) Concentration in Sample (µmol/L)= (Abs. of Sample – Abs. of Sample Blank)
X 239 (µmol/L)
Assay procedure: 2 - Direct Bilirubin End Point (Differential)
Sample Blank /  Control
Blank
Sample/ Control
Reagent R1 100 µl 100 µl 
Reagent R2                     — 50 µl
Reagent R4 1000 µl 1000 µl
Sample / Control 100 µl 100 µl 
Mix, let stand at room temperature for EXACTLY 5 minutes and read the absorbance
of sample against the sample blank. 
Calculation:
Concentration in Sample (mg/dl) = (Abs. of Sample – Abs. of Sample Blank) X 14
(mg/dl) Concentration in Sample (µmol/L)= (Abs. of Sample – Abs. of Sample Blank)
X 239 (µmol/L)
ENZYME ASSAY
A portion of liver was taken from all the groups, and a 30% w/v homogenate was
prepared in 0.9% buffered KCl (pH 7.4) for the estimation of  protein,  superoxide
dismutase (SOD), catalase (CAT), glutathione (GSH) and malondialdehyde (MDA).
1. Lipid Peroxidation140: 
Malondialdehye, formed from the breakdown of polyunsaturated fatty acids,
serves  as  a  convenient  index  for  determining  the  extent  of  peroxidation  reaction.
Malondialdehye reacts with thiobarbituric acid (TBA) to produce red colored species
which is measured at 532 nm.
Reagents:
1. TBA-TCA-HCl reagent.
15% w/v TCA, 0.375 %w/v TBA and 0.25 N HCl. 
This  solution  was  mildly  heated  to  assist  the  dissolution  of  TBA1  ml  of  liver
homogenate  was  combined  with  2  ml  of  TCA-TBA-HCL  reagent  and  mixed
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thoroughly. The solution was heated for 15 min. in a boiling water bath. After cooling,
the flocculent precipitate was removed by centrifugation at 1000 rpm for 10 min. the
absorbance of the supernatant was measured at 532 nm against a blank that contains
all the reagents minus the liver homogenate. The malondialdehyde concentration of
the sample can be calculated using an extinction coefficient of 1.56x105M-1cm-1
Malondialdehyde concentration (M) =      Absorbance/1.56 x 105
2. Estimation of Catalase141
In the presence of catalase, H2O2 shows a continual decrease in absorbane in UV
range.  The  decomposition  of  H2O2 can  be  followed  directly  by  the  decrease  in
absorbance at  240nm (E240  = 0.00394 ±0.0002 ltr  mmol-1 mm-1).  The difference in
absorbance (∆ A 240) per unit time is a measure of the catalase activity.
Reagents: 
1. PBS 50 mM; pH7.0
Dissolve (a) 6.81 of KH2PO4 and (b) in the proportion 1:1.5(v/v).
2. H2O2 (0.17 mM): dilute 0.16 ml of (30%w/v) H2O2 with Phosphate buffer to
100 ml.
The catalase activity was determined spectrophotometrically according to the protocol
of Claiborne (1985).The reaction mixture (2 ml) contained 1.95 ml 10 mM H2O2 in
60  mM  phosphate  buffer  (pH  7.0).The  reaction  was  started  by  adding  0.05  ml
supernatant and the absorbance was followed for 3 min at 240 nm. Phosphate buffer
(60  mM,  pH  7.0)  was  used  as  a  reference.  The  extinction  coefficient  of  0.04
mM−1cm−1 was used to determine the specific activity of catalase. A unit of catalase is
defined as the quantity, which decomposes 1.0µmole of H2O2  per min at pH 7.0 at
250C, while this H2O2 concentration falls from 10.3to 9.2mM.The data was expressed
as U/mg protein
4. Estimation of glutathione (GSH)142
Principle:  GSH  is  a  non-protein  compound  containing  sulphydryl  group  in  its
structure. DTNB (5,5’ di thio bis (2-Nitrobenzoic acid) is a disulfide chromagen that is
reduced by sulphydryl  compounds to an intensly yellow coloured compound.  The
absorbance  of  the  reduced  chromagen  is  measured  at  412  nm  and  is  directly
proportional to the GSH concentration.
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Reagents:
1. 10% Trichloroacetic acid (TCA)
2. Phosphate buffer (0.2M) pH 8.0
0.218 g Sodium dihydrogen phosphate and 2.641 g disodium hydrogen
phosphate in 100 ml distilled water
3. DTNB (0.6 mM) (pH 8)
11.9 mg in 50 ml Phosphate buffer 
GSH was  measured  by  the  method of  Moran  et  al  (1979).The  liver  homogenate
proteins  were  precipitated  by  10%  TCA,  centrifuged  and  the  supernatant  was
collected. 1 ml of supernatant was mixed with 6 ml of 0.2 M Phosphate buffer pH 8.0
and  1  ml  0.6  mM  DTNB  and  incubated  for  10  min  at  room  temperature.  The
absorbance of the samples was recorded against the blank at 412 nm and the GSH
concentration was calculated from the standard curve by multiplying with the dilution
factor (mannervik1985; tetza 1969)
Isolation of liver
Liver was carefully removed and washed with ice cold saline solution and pressed
between pads of filter paper and weighed. A portion of the liver was preserved in 10%
v/v neutral formalin for histopathological studies.
Histopathological Examination
A  portion  of  liver  tissue  was  preserved  in  10%  formaldehyde  solution  for
histopatholigical studies. Haematoxyline and eosin were used for the staining agent
and later microscopic slides of the liver photographed at the 100x magnification.
Statistical analysis
The data were expressed as mean±SEM values and tested with one way analysis of
variance  (ANOVA)  followed  by  the  Dunnett’s  multiple  comparison  test.p<0.05
consider as a significant value.
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RESULTS
RESULTS
Phytochemical constituents present in the methanolic extract of Polygonum 
glabrum.
Phytoconstituents Presence or Absence
AbsentCarbohydrates +
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Glycosides +
Fixed oils and fats -
Gums & mucilage -
Potein & amino acids +
Saponins +++
Tannins +
Phytosterols ++
Flavonoids ++
Alkaloids +++
Percentage yield after extraction with methanol (70%)
Plant name : Polygonum glabrum Willd
Part used : Whole plant
Solvent used : Methanol
Yield : 13 grams
% Yield : 7.5%
Acute oral toxicity 
Acute oral toxicity was carried out according to OECD guideline. MPG was safe upto
2000mg/kg.
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Acute Toxicity Record Sheet of Polygonum glabrum Willd
Title: Evaluation of LD50   Polygonum glabrum Willd
Drug: Polygonum glabrum Willd                                         Dose: 2000 mg/kg BW                   Species: Albino mice Sex: Male & Female
Duration: 24 hours
S.no
.
Code Toxicity Time
 
Of  Death
Observation
Onset Stop Skin 
colour
Eyes Res
p
CNS Tre Con Sali Dia
h
Slee
p
Leth Co
m
1. MPG x x x x x x x X x x X x x X
(*TRE-Tremor, CON-Convulsions, SALI- Salivation, Diah - Diarrhea, LET-Lethargy)                      x = Negative,  = Positive
MPG: Methanolic extract of Polygonum glabrum Willd                                       
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Effect of extract of methanolic extract of Polygonum glabrum willd on liver 
weight.
Antitubercular  drugs  (Rifampicin+Isoniazied)  treatment  in  rats  resulted  in
enlargement  of  liver  which  was  evident  by increase  in  the  wet  liver.  The  groups
treated  with  standard  silymarin  50mg/kg  (p<0.05)  and  MPG  200mg/kg  (non-
significant),  400mg/kg (p<0.05) extract  showed significant restoration of wet  liver
weight.
Effect of methanolic extract of Polygonum glabrum willd on serum biochemical 
markers in RIF/INH induced hepatoxicity in rats.
The  damage  to  the  structural  integrity  of  liver  is  commonly  assessed  by  the
determination  of  serum  amnino-transferas  activities.  The  liver  weight  and  SGPT,
SGOT, ALP, bilirubin and total protein.
SGOT
Rifampicin+Isoniazied administration resulted in  significant  (p<0.001) elevation of
SGOT levels as compared to normal group. Treatment with standard drug silymarin
50mg/kg  showed  significantly  (p<0.01)  reduction  of  SGOT level  as  compared  to
control group. Administration of extract MPG 200mg/kg and 400mg/kg had showed
significant reduction of SGOT (p<0.05, p<0.01) as compared to control group.
SGPT
Rifampicin+Isoniazied administration resulted in  significant  (p<0.001) elevation of
SGPT levels as compared to normal group. Treatment with standard drug silymarin
50mg/kg showed significantly (p<0.001)  reduction of  SGPT level  as  compared to
control group. Administration of extract MPG 200mg/kg and 400mg/kg had showed
significant reduction of SGPT level (p<0.01, p<0.001) as compared to control group.
ALP
Rifampicin+Isoniazied administration resulted in significant (p<0.001) elevation of
ALP levels as compared to normal group. Treatment with standard drug silymarin
50mg/kg showed significantly (p<0.001) reduction of ALP level as compared to
control  group.  Administration  of  extract  MPG  200mg/kg  and  400mg/kg  had
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showed significant reduction of ALP level (p<0.01, p<0.05) as compared to control
group.
Total Protein
Rifampicin+Isoniazied administration resulted in significant (p<0.001) elevation of
total  protein levels as compared to normal group. Treatment with standard drug
silymarin 50mg/kg showed significantly (p<0.001) reduction of total protein level
as  compared  to  control  group.  Administration  of  extract  MPG  200mg/kg  and
400mg/kg  had  showed  significant  reduction  of  total  bilirubin  level  (p<0.001,
p<0.01) and direct bilirubin level (p<0.0)as compared to control group.
Bilirubin
Rifampicin+Isoniazied administration resulted in significant (p<0.001) elevation of
total  and  direct  bilirubin  levels  as  compared  to  normal  group.  Treatment  with
standard drug silymarin 50mg/kg showed significantly (p<0.001) reduction of total
and direct bilirubin level as compared to control group. Administration of extract
MPG 200mg/kg and 400mg/kg had showed significant reduction of total (p<0.001,
p<0.05) and direct bilirubin level (p<0.01, p<0.05) as compared to control group
Effect of methanolic extract of  Polygonum glabrum Willd on in-vivo Antioxidant
parameters.
Catalase RCIN and INH treatment caused a significant (P<0.001) decrease in the
level of catalase, in liver tissue when compared with control group (table 3). The
liver of silymarin 50mg/kg treated animals showed a significant increase (p<0.001)
in  antioxidant  enzymes  levels  compared  to  INH  and  RCIN  treated  rats.The
treatment  of  MPG at  the doses  of  200 and 400 mg/kg resulted in  a  significant
(p<0.01, p<0.001) increase of enzymic antioxidants when compared to RCIN and
INH treated rats. 
GSH   
RCIN and INH treatment caused a significant (P<0.001) decrease in the level of
GSH in liver  tissue when compared  with control  group  (table  3).  The  liver  of
silymarin  50mg/kg  treated  animals  showed  a  significant  increase  (p<0.001)  in
antioxidant enzymes levels of GSH as compared to INH and RCIN treated rats. The
treatment  of  MPG at  the doses  of  200 and 400 mg/kg resulted in  a  significant
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(p<0.001, p<0.001) increase of enzymic antioxidants of GSH when compared to
RCIN and INH treated rats. 
LPO
RCIN and INH treatment caused a significant (P<0.001) decrease in the level of
LPO in  liver  tissue  when compared  with  control  group  (table  3).  The  liver  of
silymarin  50mg/kg  treated  animals  showed  a  significant  increase  (p<0.001)  in
antioxidant enzymes levels of LPO as compared to INH and RCIN treated rats. The
treatment  of  MPG at  the doses  of  200 and 400 mg/kg resulted in  a  significant
(p<0.05,  p<0.001) increase  of  enzymic  antioxidants  of  LPO when compared to
RCIN and INH treated rats. 
Department of pharmacology                                                                                                                                            Page 56
Table 1: Effect of of methanolic extract of Polygonum glabrum Willd on serum biochemical parameters.
GROUPS Liver weigt g/100 g 
BW
SGPT U/L SGOT U/L ALP U/L
Normal control 2.84±0.12 31.86±2.34 51.94±1.64 76.87±1.80
Positive control (CCl4 1.5 ml/kg) 3.14±0.09a 102.3±2.34a 165.6±1.82a 212.3±3.05a
Standard (Silymarin, 100 mg/kg) 2.77±0.48 * 43.64±2.12*** 89.89±1.13** 123.3±2.05***
EME  (200 mg/kg) 3.12±0.15ns 38.59±2.20** 68.02±1.62* 142.7±1.83**
EME  (400 mg/kg) 2.98±0.09* 47.05±2.22*** 87.70±1.51** 159.0±2.33*
All the values are expressed as mean±SEM, ns= not significant, N=6, One way analysis of variance (ANOVA) followed by 
multiple comparison Dunnett’s test, *p<0.05, **p<0.01 and ***p<0.001 as compared to Normal control group. and ap<0.001 
as compared to Normal group.
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Fig.no.1: Effect of of methanolic extract of Polygonum glabrum Willd on serum SGPT.
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L
All  the
values are expressed as mean±SEM, ns= not significant, N=6, One way analysis of variance
(ANOVA) followed by multiple comparison Dunnett’s test ***p<0.001 as compared to Normal
control group. and ap<0.001 as compared to Normal group.
Fig.no.2: Effect of of methanolic extract of Polygonum glabrum Willd on serum SGOT.
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GROUPS Total protein 
(g/dl)
Bilirubin (mg/dl)
Total Direct
Normal control 10.54±0.73 0.18±0.00 0.18±0.02
 Control (RIF+INH) 3.29±0.35a 2.10±0.33a 0.54±0.03a
Standard (Silymarin, 
50 mg/kg)
7.56±0.34*** 0.29±0.02*** 0.33±0.01***
MPG  (200 mg/kg) 6.92±0.33** 0.33±0.02*** 0.30±0.01**
MPG  (400 mg/kg) 8.56±0.46*** 0.41±0.01* 0.40±0.01*
All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed by multiple comparison Dunnett’s test, *p<0.05 and **p<0.01 as compared to Normal
control group. and ap<0.001 as compared to Normal group.
Fig.no.3: Effect of of methanolic extract of Polygonum glabrum Willd on serum ALP.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by  multiple  comparison  Dunnett’s  test,  *p<0.05,  **p<0.01  and  ***p<0.001  as
compared to Normal control group. and ap<0.001 as compared to Normal group.
Table 2: Effect of of methanolic extract of Polygonum glabrum Willd on serum total protein
and bilirubin. 
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by  multiple  comparison  Dunnett’s  test,  *p<0.05,  **p<0.01  and  ***p<0.001  as
compared to Normal control group and ap<0.001 as compared to Normal group.
Fig.4: Effect of of methanolic extract of Polygonum glabrum Willd on serum total protein.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by  multiple  comparison  Dunnett’s  test  **p<0.01  and  ***p<0.001  as  compared  to
Normal control group and ap<0.001 as compared to Normal group
Fig.5: Effect of of methanolic extract of Polygonum glabrum Willd on serum total bilirubin.
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All the values are expressed as mean±SEM, N=6, One way analysis of variance (ANOVA) 
followed by multiple comparison Dunnett’s test, *p<0.05 and ***p<0.001 as compared to 
Normal control group. and ap<0.001 as compared to Normal group
Fig.6: Effect of of methanolic extract of Polygonum glabrum Willd on serum direct 
bilirubin.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by  multiple  comparison  Dunnett’s  test,  *p<0.05,  **p<0.01  and  ***p<0.001  as
compared to Normal control group. and ap<0.001 as compared to Normal group.
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Table.4: Effect of of methanolic extract of Polygonum glabrum Willd on Invivo Antioxidant 
parameters.
Treatment group
In-vivo Antioxidant parameters
CATALASA 
µm/mg tissue
GSH
µm/mg tissue
LPO
µm of /H2O2/mg 
tissue
Normal 72.33±0.81 3.17±0.05 9.97±0.27
Control (RIF+INH) 30.63±0.84a 1.13±0.06a 24.39±0.59a
Standard Silymarin (50m/kg) 69.70±0.74*** 2.42±0.07*** 15.64±0.37***
MPG 200mg/kg 46.59±0.91** 1.93±0.01*** 15.90±0.65*
MPG 400mg/kg 60.57±0.82*** 1.80±0.02*** 17.53±0.58***
All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by  multiple  comparison  Dunnett’s  test,  *p<0.05,  **p<0.01  and  ***p<0.001  as
compared to Normal control group. and ap<0.001 as compared to Normal group.
Fig.no.7: Effect of Polygonum glabrum Willd on catalase level in RCIN and INH -induced 
hepatotoxicity rats.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed  by multiple  comparison  Dunnett’s  test,  **p<0.01  and  ***p<0.001  as  compared  to
Normal control group. and ap<0.001 as compared to Normal group. 
Fig.no.8: Effect of Polygonum glabrum Willd on GSH level in RCIN and INH -induced 
hepatotoxicity rats.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed by multiple  comparison Dunnett’s  test  ***p<0.001 as  compared to Normal  control
group. and ap<0.001 as compared to Normal group.
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Fig.no.9: Effect of Polygonum glabrum Willd on LPO level in RCIN and INH -induced 
hepatotoxicity rats.
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All  the  values  are  expressed  as  mean±SEM, N=6,  One way analysis  of  variance  (ANOVA)
followed by multiple comparison Dunnett’s test *p<0.05, **p<0.01and  ***p<0.001 as compared
to Normal control group. and ap<0.001 as compared to Normal group.
Histopathological studies on liver in antitubercular drug induced (RIF+INH) 
hepatotoxicity.
Normal group: The architecture of liver parenchyma appeared intact. There were seen scattered
mononuclear inflammatory cells and epithelioid granulomas with in the parenchyma. Periportal
and perivenular infiltration by aggregates of mononuclear inflammatory cells were seen. Some of
the central veins show thrombosis.
Control group:  The architecture of liver parenchyma appeared partly effaced. There are seen
degenerating hepatocytes amidst normal hepatocytes. The parenchyma showed areas of necrosis
with  mixed  inflammatory  infiltration.  Periportal  infiltration  by  mixed  inflammatory  cells
comprising of lymphocytes, neutrophils and histocytes were seen. 
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Standrad Silymarin group: The architecture of liver parenchyma appeared intact. Focal areas
showed  degenerating  and  regenerating  hepatocytes.The  parenchyma  showed  aggregates  of
lymphocytes,  macrophages  and  histocytes.  Periportal  and  perivenular  infiltration  by
mononuclear inflammatory cells comprising of lymphocytes and histocytes were seen. 
MPG 200mg/kg group: The architecture of liver parenchyma appeared intact. There were seen
some regenerating hepatocytes amidst normal hepatocytes. The parenchyma showed aggregates
of  mononuclear  inflammatory  cells.  Periportal  and  perivenular  infiltration  by  scattered
mononuclear inflammatory cells comprising of lymphocytes and histocytes were seen. bile duct
proliferation was seen at some areas.
MPG 400mg/kg group: The architecture of liver parenchyma appeared intact. There were seen
dilated and congested sinusoids between the hepatocytes. The parenchyma shows few epitheloid
granulomas. Periportal and perivenular infiltration by scattered mononuclear inflammatory cells
were seen. Some of the central veins showed congestion.
Histopathology of Liver
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A: Normal group
B: Control (RIF+INH)
C:Standard (Silymarin 50mg/kg)
D: MPG 200mg/kg
E: MPG 400mg/kg
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                                                            DISCUSSION
                     Drug-induced hepatotoxicity is a potentially serious adverse effect of the currently
used anti-tubercular chemotherapeutic regimens containing RCIN and INH. The conversion of
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monoacetyl hydrazine, a metabolite of INH, to a toxic metabolite via cytochrome P450 leads to
hepatotoxicity.  RCIN induces cytochrome P450 enzyme resulting an increased production of
toxic metabolites from acetyl hydrazine (AcHz). RCIN can also increase the metabolism of INH
to isonicotinic acid and hydrazine, both of which are hepatotoxic.  The plasma half-life of AcHz
(metabolite  of  INH)  is  shortened  by  RCIN  and  AcHz  is  quickly  converted  to  its  active
metabolites by increasing the oxidative elimination rate of AcHz, which is related to the higher
incidence  of  liver  necrosis  caused  by RCIN  and  INH combination  143.  In  addition  to  these
mechanisms;  oxidative  stress  induced  hepatic  injury is  one  of  the  important  mechanisms  in
hepatotoxicity produced by anti-tubercular drugs 144,145.Earlier it has been well documented that
both ALT and AST are considered among the most sensitive markers to assess hepatocellular
damage leading to liver cell necrosis 146,147.
ALP, which is secreted from the lysosomes, is also a marker enzyme for assessing liver damage.
Slight to moderate increases in ALP (1-2 times normal) occurred in liver disorders148. Estimating
the  activities  of  serum  marker  enzymes,  like  AST,  ALT,  ALP,  total  bilirubin,  can  make
assessment of liver function. When liver cell plasma membrane is damaged, a variety of enzymes
normally located in the cytosol are released in to the blood stream. Their estimation in the serum
is a useful quantitative marker of the extent and type of hepatocellular damage.
The enhanced activities of these serum marker enzymes observed in RCIN and INH treated rats
in  our  study correspond  to  the  extensive  liver  damage  induced  by RCIN and  INH.  Results
indicate that MPG administration could blunt RCIN and INH -induced increase in activities of
different marker enzymes of heptocellular injury, viz. AST, ALT, ALP, total bilirubin and total
protein, (Table 1-2) suggesting that MPG possibly has a protective influence against RCIN and
INH  induced  hepatocellular  injury and  degenerative  changes.  Antitubercular  drugs  mediated
oxidative damage is generally attributed to the formation of free radicals, which act as stimulator
of lipid peroxidation and source for destruction and damage to the cell membrane149.
In previous report suggested that, there did not seem to be clear evidence that INH proves much
more injuries than RIF and, in this connection, they consider that it is the combination of these
two drugs that confer the additive, or even synergistic, potential of liver toxicity than either agent
alone, as conjectured150,151. In our study, RCIN and INH treatment produced the elevation in the
levels of LPO. Treatment of the rats with MPG significantly reduced the elevated levels of LPO.
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Alterations  of  various  cellular  defense  mechanisms  consisting  of  enzymatic  antioxidant
components [superoxide dismutase (SOD), catalase, GSH have been reported in RCIN and INH
-induced hepatoxicity (Table 3). The RCIN and INH administered animals exhibited significantly
(p<0.001) low levels of hepatic enzymatic antioxidant components, and significantly increased
with  co-administration  of  MPG (200  and 400  mg/kg)  at  the  all  the  doses  and  in  silymarin
treatment group after  21 days.  On the day of  21st  enzymatic  antioxidant components levels
significantly increased with co-administration of MPG at the lower and higher doses (200 and
400 mg/kg) and in silymarin treated group. 
Histopathological studies, treatment with different doses of MPG produced mild portal triaditis
and absence of necrosis when compared with control. Treatment with silymarin also shows mild
portal triaditis and absence of necrosis and vacuoles. All these results indicate a hepatoprotective
potential  of  the  extract.  The  results  of  the  present  study  suggested  that  MPG  possess
hepatoprotective  activity  against  the  hepatotoxicity  induced  by  the  combination  of  two
antitubercular drugs.
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CONCLUSION
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In conclusion, the results of this experiment demonstrate a potent hepatoprotective action of 
methanolic extract of Polygonm glabrum Willd in Rifampicin and INH-induced oxidative stress 
and liver toxicity in rats. Such effects can be correlated directly with its ability to reduce lipid 
peroxidation and enhance the antioxidant defence status. Thus methanolic extract of Polygonm 
glabrum Willd may be used as a safe and effective alternative chemo preventive and protective 
agent in the management of liver diseases.
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SUMMARY
The present study was aimed to assess the hepatoprotective activity of methanolic extract  of
Polygonum glabrum Willd.
LD50 studies  were  conducted  in  albino rats  with  methanolic  extract  of  polygonum glabrum
according to  OECD guidelines  423 and was found safe upto the dose level  of  2000 mg/kg
confirming its non-toxic nature. The hepatoprotective activity was studied in antitubercular drugs
induced hepatoxic animal models. The physical parameters such as liver weight and biochemical
parameters  like SGOT,  SGPT,  ALP,  Total  protein  and Bilirubin.  Antioxidant  parameters  like
catalase, GSH and LPO and histopathology reports of livers were also considered to confirm
hepatoprotection. 
Antitubercular drugs induced hepatotoxicity was significantly prevented by pretreatment with
methanolic extract of Polygonum glabrum Willd. Decrease in wet liver weight and reduction in
biochemical parameters levels like serum SGOT, SGPT, ALP, Total protein bilirubin and increase
in  ROS  scavenging  enzyme  activities  such  as  catalase  GSH  and  LPO  after  treatment  with
methanolic extract of Polygonum glabrum Willd confirmed the hepatoprotective effect of ectract
under study. In liver injury models in rats restoration of hepatic cells with minor fatty changes
and  absence  of  necrosis  after  treatment  with  extract  was  observed  indicating  satisfactory
hepatoprotection.
Based  on improvement  in  serum marker  enzyme levels,  physical  parameter  and  antioxidant
parameters and histopathological studies it was concluded that methanolic extract of Polygonum
glabrum possesses significant hepatoprotective activity in the doses used.
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